Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR)

[Display omitted] •Morpholine is a versatile nucleus as it involved in wide range of pharmacological activities.•The present review covers synthetic medicinal chemistry, SAR and pharmacological significance of morpholine derivatives.•Various morpholine containing drugs under clinical trial having di...

Full description

Saved in:
Bibliographic Details
Published inBioorganic chemistry Vol. 96; p. 103578
Main Authors Kumari, Archana, Singh, Rajesh K.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.03.2020
Subjects
Chemistry, Pharmaceutical
Drug Design
Humans
Morpholine
Morpholines - chemistry
Morpholines - pharmacology
Pharmacokinetic
Pharmacological profile
Pharmacophore
Structure-Activity Relationship
Structure–activity relationship (SAR)
DMSO
FLT3
Structure–activity relationship (SAR)
TFA
NF-κB
PI3K
GSK3
IC50
mTOR
NPY-Y5
CD38
WHO
DPPH
MIC
IL-2
Pharmacokinetic
SV2
SQS
APVM
PIP3
HCV
ERK
FDA
SAR
CK2
BASF
MCSF
PDK
BRD4
DNA-PK
ISO
ADME
EGF
IKK
Akt
Pharmacological profile
COX
ACP
TB
DHFR
Morpholine
HER
HIV
TNF-α
DNA
MAPK or MEK
PDGF
Raf
Pharmacophore
ATR
Online AccessGet full text
ISSN0045-2068
1090-2120
1090-2120
DOI10.1016/j.bioorg.2020.103578

Cover

Abstract [Display omitted] •Morpholine is a versatile nucleus as it involved in wide range of pharmacological activities.•The present review covers synthetic medicinal chemistry, SAR and pharmacological significance of morpholine derivatives.•Various morpholine containing drugs under clinical trial having different mechanism of actions are also mentioned. Morpholine is a versatile moiety, a privileged pharmacophore and an outstanding heterocyclic motif with wide ranges of pharmacological activities due to different mechanisms of action. The ability of morpholine to enhance the potency of the molecule through molecular interactions with the target protein (kinases) or to modulate the pharmacokinetic properties propelled medicinal chemists and researchers to synthesize morpholine ring by the efficient ways and to incorporate this moiety to develop various lead compounds with diverse therapeutic activities. The present review primarily focused on discussing the most promising synthetic leads containing morpholine ring along with structure–activity relationship (SAR) to reveal the active pharmacophores accountable for anticancer, anti-inflammatory, antiviral, anticonvulsant, antihyperlipidemic, antioxidant, antimicrobial and antileishmanial activity. This review outlines some of the recent effective chemical synthesis for morpholine ring. The review also highlighted the metabolic liability of some clinical drugs containing this nucleus and various researches on modified morpholine to enhance the metabolic stability of drugs as well. Drugs bearing morpholine ring and those under clinical trials are also mentioned with the role of morpholine and their mechanism of action. This review will provide the necessary knowledge base to the medicinal chemists in making strategic structural changes in designing morpholine derivatives.
AbstractList Morpholine is a versatile moiety, a privileged pharmacophore and an outstanding heterocyclic motif with wide ranges of pharmacological activities due to different mechanisms of action. The ability of morpholine to enhance the potency of the molecule through molecular interactions with the target protein (kinases) or to modulate the pharmacokinetic properties propelled medicinal chemists and researchers to synthesize morpholine ring by the efficient ways and to incorporate this moiety to develop various lead compounds with diverse therapeutic activities. The present review primarily focused on discussing the most promising synthetic leads containing morpholine ring along with structure-activity relationship (SAR) to reveal the active pharmacophores accountable for anticancer, anti-inflammatory, antiviral, anticonvulsant, antihyperlipidemic, antioxidant, antimicrobial and antileishmanial activity. This review outlines some of the recent effective chemical synthesis for morpholine ring. The review also highlighted the metabolic liability of some clinical drugs containing this nucleus and various researches on modified morpholine to enhance the metabolic stability of drugs as well. Drugs bearing morpholine ring and those under clinical trials are also mentioned with the role of morpholine and their mechanism of action. This review will provide the necessary knowledge base to the medicinal chemists in making strategic structural changes in designing morpholine derivatives.
[Display omitted] •Morpholine is a versatile nucleus as it involved in wide range of pharmacological activities.•The present review covers synthetic medicinal chemistry, SAR and pharmacological significance of morpholine derivatives.•Various morpholine containing drugs under clinical trial having different mechanism of actions are also mentioned. Morpholine is a versatile moiety, a privileged pharmacophore and an outstanding heterocyclic motif with wide ranges of pharmacological activities due to different mechanisms of action. The ability of morpholine to enhance the potency of the molecule through molecular interactions with the target protein (kinases) or to modulate the pharmacokinetic properties propelled medicinal chemists and researchers to synthesize morpholine ring by the efficient ways and to incorporate this moiety to develop various lead compounds with diverse therapeutic activities. The present review primarily focused on discussing the most promising synthetic leads containing morpholine ring along with structure–activity relationship (SAR) to reveal the active pharmacophores accountable for anticancer, anti-inflammatory, antiviral, anticonvulsant, antihyperlipidemic, antioxidant, antimicrobial and antileishmanial activity. This review outlines some of the recent effective chemical synthesis for morpholine ring. The review also highlighted the metabolic liability of some clinical drugs containing this nucleus and various researches on modified morpholine to enhance the metabolic stability of drugs as well. Drugs bearing morpholine ring and those under clinical trials are also mentioned with the role of morpholine and their mechanism of action. This review will provide the necessary knowledge base to the medicinal chemists in making strategic structural changes in designing morpholine derivatives.
Morpholine is a versatile moiety, a privileged pharmacophore and an outstanding heterocyclic motif with wide ranges of pharmacological activities due to different mechanisms of action. The ability of morpholine to enhance the potency of the molecule through molecular interactions with the target protein (kinases) or to modulate the pharmacokinetic properties propelled medicinal chemists and researchers to synthesize morpholine ring by the efficient ways and to incorporate this moiety to develop various lead compounds with diverse therapeutic activities. The present review primarily focused on discussing the most promising synthetic leads containing morpholine ring along with structure-activity relationship (SAR) to reveal the active pharmacophores accountable for anticancer, anti-inflammatory, antiviral, anticonvulsant, antihyperlipidemic, antioxidant, antimicrobial and antileishmanial activity. This review outlines some of the recent effective chemical synthesis for morpholine ring. The review also highlighted the metabolic liability of some clinical drugs containing this nucleus and various researches on modified morpholine to enhance the metabolic stability of drugs as well. Drugs bearing morpholine ring and those under clinical trials are also mentioned with the role of morpholine and their mechanism of action. This review will provide the necessary knowledge base to the medicinal chemists in making strategic structural changes in designing morpholine derivatives.Morpholine is a versatile moiety, a privileged pharmacophore and an outstanding heterocyclic motif with wide ranges of pharmacological activities due to different mechanisms of action. The ability of morpholine to enhance the potency of the molecule through molecular interactions with the target protein (kinases) or to modulate the pharmacokinetic properties propelled medicinal chemists and researchers to synthesize morpholine ring by the efficient ways and to incorporate this moiety to develop various lead compounds with diverse therapeutic activities. The present review primarily focused on discussing the most promising synthetic leads containing morpholine ring along with structure-activity relationship (SAR) to reveal the active pharmacophores accountable for anticancer, anti-inflammatory, antiviral, anticonvulsant, antihyperlipidemic, antioxidant, antimicrobial and antileishmanial activity. This review outlines some of the recent effective chemical synthesis for morpholine ring. The review also highlighted the metabolic liability of some clinical drugs containing this nucleus and various researches on modified morpholine to enhance the metabolic stability of drugs as well. Drugs bearing morpholine ring and those under clinical trials are also mentioned with the role of morpholine and their mechanism of action. This review will provide the necessary knowledge base to the medicinal chemists in making strategic structural changes in designing morpholine derivatives.
ArticleNumber 103578
Author Singh, Rajesh K.
Kumari, Archana
Author_xml – sequence: 1
  givenname: Archana
  surname: Kumari
  fullname: Kumari, Archana
  organization: Department of Pharmaceutical Chemistry, Rayat-Bahra Institute of Pharmacy, Dist. Hoshiarpur, 146104 Punjab, India
– sequence: 2
  givenname: Rajesh K.
  surname: Singh
  fullname: Singh, Rajesh K.
  email: rksingh244@gmail.com
  organization: Department of Pharmaceutical Chemistry, Shivalik College of Pharmacy, Nangal, Dist. Rupnagar, 140126 Punjab, India
BackLink https://www.ncbi.nlm.nih.gov/pubmed/31978684$$D View this record in MEDLINE/PubMed
BookMark eNqFUUtr3DAQFiWh2aT9B6XomB681cOW5RwKIX1CQqCPs5Dl2XgWr-VIcmD766utk0sPzWlgvgfzzXdKjkY_AiFvOFtzxtX77bpF78PdWjBxWMmq1i_IirOGFYILdkRWjJVVIZjSJ-Q0xi1jnJe1eklOJG9qrXS5Ir9vfJh6P-AI1EY6t3g_Y_JzpFNvw846n9EAFEe6gw4djnagrocdxhT2F_QjwJTBiHd9yjN5mnqgGZtdmgMU1iV8wLSnAQab0I-xx4me_7j8_u4VOd7YIcLrx3lGfn3-9PPqa3F9--Xb1eV14aQSqSgtd9bJpt20StmubmXTSN3VQlcWOq7Krq00aFmJumFcqqrhnd5wq7SrhaiUPCPni-8U_P0MMZl8vINhsCPkoEbIsqpYXWueqW8fqXOb45op4M6GvXn6VyZcLAQXfIwBNsZh-psrBYuD4cwcyjFbs5RjDuWYpZwsLv8RP_k_I_uwyCA_6QEhmOgQRpfrCOCS6Tz-3-APaOusKQ
CitedBy_id crossref_primary_10_1016_j_apsb_2022_03_021
crossref_primary_10_3390_pharmaceutics16040462
crossref_primary_10_1002_jhet_4588
crossref_primary_10_1021_acs_orglett_2c00377
crossref_primary_10_1021_jacs_4c11708
crossref_primary_10_1039_D3MD00415E
crossref_primary_10_3390_scipharm88040054
crossref_primary_10_1002_ardp_202300670
crossref_primary_10_1021_acs_jmedchem_4c00230
crossref_primary_10_1007_s00706_021_02849_w
crossref_primary_10_1016_j_ejmech_2023_116034
crossref_primary_10_1055_a_1915_7794
crossref_primary_10_33380_2305_2066_2021_10_4_1__179_187
crossref_primary_10_1021_acs_jmedchem_4c03066
crossref_primary_10_1007_s12039_021_01891_9
crossref_primary_10_1016_j_bioorg_2024_107390
crossref_primary_10_1002_ejoc_202201053
crossref_primary_10_1002_jhet_4335
crossref_primary_10_1002_slct_202304846
crossref_primary_10_1016_j_ijbiomac_2024_131784
crossref_primary_10_1039_D0OB01315C
crossref_primary_10_3389_fchem_2025_1537261
crossref_primary_10_1016_j_bmcl_2022_128650
crossref_primary_10_1002_ange_202313247
crossref_primary_10_1016_j_rechem_2023_101279
crossref_primary_10_1002_ardp_202200136
crossref_primary_10_1021_acs_jpclett_3c02280
crossref_primary_10_1039_D4RA02882A
crossref_primary_10_2174_1573406418666220812152950
crossref_primary_10_1002_ardp_202100517
crossref_primary_10_1016_j_bioorg_2023_106805
crossref_primary_10_1016_j_ejmech_2023_116049
crossref_primary_10_1021_acs_biomac_1c01474
crossref_primary_10_1007_s42250_023_00783_4
crossref_primary_10_1080_10426507_2023_2232509
crossref_primary_10_1002_slct_202002779
crossref_primary_10_1039_D1SC03615G
crossref_primary_10_1016_j_molstruc_2022_132510
crossref_primary_10_3390_biomedicines10112783
crossref_primary_10_1002_anie_202313247
crossref_primary_10_1080_10406638_2022_2130369
crossref_primary_10_1186_s41181_023_00225_z
crossref_primary_10_1021_acs_joc_3c00207
crossref_primary_10_1002_slct_202304020
crossref_primary_10_1016_j_fluid_2024_114141
crossref_primary_10_1002_cbdv_202200290
crossref_primary_10_1002_asia_202200849
crossref_primary_10_1016_j_jmgm_2024_108915
crossref_primary_10_1021_acs_orglett_4c01988
crossref_primary_10_1039_D4RA02667E
crossref_primary_10_1007_s00044_024_03233_z
crossref_primary_10_1021_acs_inorgchem_1c01363
crossref_primary_10_3390_M1796
crossref_primary_10_1021_acs_joc_4c02690
crossref_primary_10_1039_D0OB01987A
crossref_primary_10_1016_j_molstruc_2024_138668
crossref_primary_10_2174_1570180819666220404084045
crossref_primary_10_1051_e3sconf_202455601051
crossref_primary_10_2174_1573406416666200512073640
crossref_primary_10_3390_jcs8090349
crossref_primary_10_1016_j_ejmech_2025_117472
crossref_primary_10_1134_S1070363223040242
crossref_primary_10_1021_acs_orglett_4c01634
crossref_primary_10_1016_j_jscs_2020_101195
crossref_primary_10_1016_j_bioorg_2023_106868
crossref_primary_10_1016_j_bmc_2025_118141
crossref_primary_10_3390_molecules29163903
crossref_primary_10_1016_j_bioorg_2024_107979
crossref_primary_10_1002_ajoc_202400048
crossref_primary_10_25040_ntsh2024_01_19
crossref_primary_10_1002_asia_202301081
crossref_primary_10_4155_fmc_2022_0141
crossref_primary_10_1039_D0OB01726D
crossref_primary_10_1016_j_jinorgbio_2024_112812
crossref_primary_10_1002_slct_202101634
crossref_primary_10_3389_fchem_2024_1403127
crossref_primary_10_1039_D2MD00076H
crossref_primary_10_1039_D1RA07749J
crossref_primary_10_1002_cbdv_202401620
crossref_primary_10_1039_D4MD00885E
crossref_primary_10_1016_j_inoche_2022_109750
crossref_primary_10_2174_1386207326666230102111810
crossref_primary_10_1039_D4DT00362D
crossref_primary_10_1016_j_tetlet_2021_153269
crossref_primary_10_1021_acs_jafc_3c03818
crossref_primary_10_1016_j_molstruc_2021_131081
crossref_primary_10_2174_1385272822666200217100344
crossref_primary_10_1039_D4OB00855C
crossref_primary_10_33380_2305_2066_2023_12_2_44_54
crossref_primary_10_1016_j_jscs_2021_101284
crossref_primary_10_1021_acs_orglett_3c01478
crossref_primary_10_1039_D3MD00718A
crossref_primary_10_1134_S1068162024020092
crossref_primary_10_2174_1568026623666230614150520
crossref_primary_10_1002_cbdv_202300257
crossref_primary_10_1039_D2CC01551J
crossref_primary_10_14233_ajchem_2023_24037
crossref_primary_10_1021_acs_orglett_4c00528
crossref_primary_10_1039_D3MD00560G
crossref_primary_10_1021_acs_jmedchem_3c02473
crossref_primary_10_3390_molecules27051641
crossref_primary_10_1021_acs_joc_2c01338
crossref_primary_10_1016_j_bioorg_2024_107597
crossref_primary_10_1016_j_bioorg_2020_104245
crossref_primary_10_1002_cmdc_202000305
crossref_primary_10_1016_j_eurpolymj_2023_112490
crossref_primary_10_1016_j_jbc_2025_108407
crossref_primary_10_3390_molecules27227785
crossref_primary_10_1016_j_ejmech_2022_115038
crossref_primary_10_1002_ange_202501424
crossref_primary_10_1002_jhet_4689
crossref_primary_10_1039_D1NJ04198C
crossref_primary_10_1021_acs_joc_4c00743
crossref_primary_10_1002_chem_202301888
crossref_primary_10_3390_cancers17050759
crossref_primary_10_1002_ejoc_202100483
crossref_primary_10_1007_s00289_024_05552_y
crossref_primary_10_1039_D2MD00023G
crossref_primary_10_1021_acs_joc_2c02339
crossref_primary_10_1016_j_imu_2023_101162
crossref_primary_10_1039_D1NJ04543A
crossref_primary_10_1016_j_jaap_2022_105667
crossref_primary_10_1007_s10593_024_03372_6
crossref_primary_10_1002_jhet_4398
crossref_primary_10_1002_anie_202501424
crossref_primary_10_1002_jhet_4795
crossref_primary_10_1039_D3MD00511A
crossref_primary_10_1002_ardp_202400821
crossref_primary_10_1002_slct_202201706
crossref_primary_10_1021_acschemneuro_0c00729
crossref_primary_10_1016_j_bmc_2022_116739
crossref_primary_10_1016_j_biopha_2024_116516
crossref_primary_10_3390_ijms25168874
crossref_primary_10_1111_cbdd_14512
crossref_primary_10_1016_j_antiviral_2023_105766
crossref_primary_10_1021_acsmedchemlett_4c00237
crossref_primary_10_1111_cbdd_14599
crossref_primary_10_3390_ijms252312873
crossref_primary_10_1016_j_ejmech_2024_116284
crossref_primary_10_1021_acs_jmedchem_4c03017
crossref_primary_10_1002_jhet_4837
crossref_primary_10_1007_s10895_023_03304_1
crossref_primary_10_1038_s41598_022_07533_5
crossref_primary_10_3390_ijms23094706
crossref_primary_10_1016_j_ejmech_2024_116844
crossref_primary_10_3390_catal13091279
Cites_doi 10.3390/molecules22040613
10.1021/jm900851f
10.1021/jm401842e
10.1016/S0092-8674(00)81334-3
10.1056/NEJMe1812483
10.1200/JCO.2015.64.8808
10.1080/14786410802090359
10.1016/j.tetlet.2004.09.185
10.2174/1389557518666180330112416
10.1016/S1054-3589(08)60129-5
10.3390/md15100310
10.1016/j.tet.2013.03.067
10.1021/jo102471r
10.1016/j.pbb.2010.12.019
10.1158/0008-5472.CAN-09-0299
10.1016/j.bmcl.2009.08.038
10.1016/j.pbb.2010.07.020
10.1007/s00044-011-9891-y
10.1039/C5QO00060B
10.1158/1535-7163.MCT-05-0333
10.1021/jm061121y
10.1016/j.biocel.2017.03.015
10.1158/1535-7163.MCT-11-0535
10.1134/S1070428013060018
10.5530/ijper.53.3.68
10.3762/bjoc.11.59
10.1016/j.bmcl.2010.03.046
10.1016/j.drup.2014.04.002
10.1016/j.jpba.2009.03.011
10.1634/theoncologist.2014-0229
10.1016/j.bmcl.2010.07.104
10.1007/BF00323011
10.1016/j.bmcl.2016.11.032
10.1021/np0500124
10.1111/j.1365-2125.1993.tb04196.x
10.3390/molecules24030630
10.1016/j.tet.2016.12.052
10.1136/bmj.c4737
10.1021/jm9013828
10.1016/j.bmc.2015.09.034
10.3892/ol.2011.474
10.1016/j.biopha.2016.11.125
10.1016/j.bmc.2004.06.022
10.1016/j.ejmech.2004.09.003
10.1016/j.bmc.2012.08.023
10.1002/anie.200602343
10.1016/j.bioorg.2019.103021
10.1186/1471-2121-7-33
10.1007/BF03189545
10.1016/j.bmcl.2017.06.010
10.1016/j.ejmech.2005.07.011
10.1021/jm800295d
10.1186/1476-4598-12-86
10.1111/j.1749-6632.1988.tb40406.x
10.1038/nchembio.293
10.1021/ml200156t
10.1158/1078-0432.CCR-05-1554
10.1186/s12887-017-0884-y
10.1124/dmd.104.000216
10.1021/acsmedchemlett.6b00135
10.24820/ark.5550190.p010.037
10.1124/jpet.110.167940
10.1007/978-94-011-3804-8
10.1038/jid.2012.335
10.1016/j.sjbs.2015.02.001
10.3390/molecules22081374
10.1021/jo201975b
10.1016/j.tetlet.2006.08.029
10.18596/jotcsa.23635
10.1128/AAC.05764-11
10.1016/S0021-9258(17)37680-9
10.1016/j.bmcl.2012.06.093
10.1021/jm501026z
10.1002/cncr.31044
10.1021/acs.jmedchem.8b01148
10.1016/j.bmcl.2011.01.065
10.1021/acsmedchemlett.8b00469
10.1016/j.molstruc.2012.02.057
10.3892/or.2017.5991
10.3390/cancers9050041
10.5012/bkcs.2008.29.8.1443
10.1016/j.ejmech.2015.05.036
10.18632/oncotarget.9501
10.1016/j.antiviral.2018.04.016
10.1155/2014/824756
10.1016/j.cell.2006.03.035
10.1016/j.ejmech.2016.05.024
10.1080/02772240400015222
10.1158/1535-7163.MCT-09-0954
10.1016/S0040-4020(96)01165-9
10.1124/dmd.106.012906
10.1158/1535-7163.MCT-12-0466
10.1016/j.bmc.2014.11.003
10.1021/acs.joc.6b01884
10.1016/S0090-9556(24)14936-7
10.1021/jm011062i
10.59566/IJBS.2010.6060
10.1007/s10593-012-0960-z
10.1186/s13058-018-1015-x
10.1039/C4RA15201H
10.1016/j.ejmech.2015.04.037
10.1021/ol300030w
10.3987/COM-94-6917
10.1016/j.ejmech.2019.02.015
10.1016/j.bmcl.2012.05.104
10.1016/j.rppnen.2017.10.009
10.1016/j.ejmech.2018.04.001
10.1158/0008-5472.CAN-04-2727
10.1016/j.fct.2013.01.052
10.1080/004982599238182
10.1038/nm1232
10.3797/scipharm.1505-16
10.3389/fphar.2018.01162
10.1002/chem.201800193
10.1200/jco.2014.32.15_suppl.2514
10.1155/2018/9872095
10.1158/1078-0432.CCR-17-0725
10.1021/acs.jmedchem.8b01262
10.1016/j.ejmech.2017.09.003
10.1016/j.bmc.2014.03.002
10.1158/0008-5472.CAN-06-4615
10.1016/j.bmc.2011.07.019
10.1158/1535-7163.MCT-09-0519
10.22159/ijpps.2017v9i11.20469
10.1200/JCO.2018.36.15_suppl.2518
10.1021/acs.biochem.6b00342
10.1038/leu.2011.339
10.1159/000448843
10.1155/2015/394257
10.1016/0924-977X(96)00023-5
10.4172/2161-0444.1000272
10.1042/CS20171158
10.1021/ml3003132
10.1021/jm501100b
10.2174/1389557516666160118112103
10.1007/s11255-017-1507-0
10.1038/nrd2926
10.1128/AAC.01677-13
10.1038/sj.bjc.6602823
10.1158/1078-0432.CCR-14-1315
10.1007/s12272-012-0407-1
10.1016/j.bmcl.2016.04.015
10.1021/jm301859s
10.1021/acs.joc.5b00049
10.1021/ml400527n
10.1007/s11060-016-2158-1
10.1021/acs.orglett.5b02516
10.1055/s-2004-816003
10.3390/ph10020051
10.1016/j.bmcl.2009.11.057
10.3892/ijo.2016.3804
10.22159/ijpps.2016v8i12.13503
10.1016/j.patbio.2006.01.012
10.1021/acs.orglett.7b02395
10.1021/jm9018788
10.1183/13993003.00098-2018
10.1158/0008-5472.CAN-07-0669
10.1128/AAC.03913-14
10.1002/anie.200800450
10.1016/j.jpba.2017.11.031
10.4103/0250-474X.57292
10.1182/blood-2003-07-2527
10.3906/kim-1512-12
10.2147/DDDT.S146521
10.1139/cjp-2017-0710
10.1021/jm401642q
10.1021/jm200688y
10.1093/nar/gkg753
10.4172/pharmaceutical-sciences.1000413
10.3390/molecules22071211
10.1021/jm400101e
10.1371/journal.pone.0132655
10.1074/jbc.M109.048553
10.1007/s00044-012-0318-1
10.1158/0008-5472.CAN-05-4275
10.1158/0008-5472.CAN-09-1751
10.1016/j.bmcl.2013.01.019
10.1111/j.1538-7836.2012.04898.x
10.1158/1535-7163.MCT-15-0365
10.1021/acs.jmedchem.8b00172
10.1007/s10637-012-9835-5
10.1002/ijc.28680
10.1158/1078-0432.CCR-10-1694
10.1021/jm1003232
10.1021/jm2009327
10.1016/0002-9394(86)90532-5
10.1016/j.jpba.2016.06.011
10.1006/excr.2000.4836
10.4236/ojd.2017.62004
10.1158/0008-5472.CAN-04-4250
10.1016/j.bmcl.2010.02.045
ContentType Journal Article
Copyright 2020 Elsevier Inc.
Copyright © 2020 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2020 Elsevier Inc.
– notice: Copyright © 2020 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1016/j.bioorg.2020.103578
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
EISSN 1090-2120
ExternalDocumentID 31978684
10_1016_j_bioorg_2020_103578
S0045206819318395
Genre Journal Article
Review
GroupedDBID ---
--K
--M
-DZ
-~X
.GJ
.~1
0R~
1B1
1RT
1~.
1~5
23N
4.4
457
4G.
53G
5GY
5VS
7-5
71M
8P~
9JM
9JN
AAAJQ
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AARKO
AARLI
AATCM
AAXUO
ABEFU
ABGSF
ABJNI
ABMAC
ABUDA
ABXDB
ABYKQ
ABZDS
ACDAQ
ACGFS
ACNCT
ACNNM
ACRLP
ADBBV
ADECG
ADEZE
ADFGL
ADMUD
ADUVX
AEBSH
AEHWI
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AFZHZ
AGEKW
AGHFR
AGRDE
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
AJSZI
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
CAG
CJTIS
COF
CS3
DM4
DOVZS
DU5
EBS
EFBJH
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FA8
FDB
FEDTE
FGOYB
FIRID
FLBIZ
FNPLU
FYGXN
G-2
G-Q
GBLVA
HLW
HMG
HMS
HMT
HVGLF
HZ~
H~9
IHE
J1W
K-O
KOM
LG5
LUGTX
LX2
LZ5
M2Y
M33
M41
MO0
MVM
N9A
O-L
O9-
OAUVE
OGGZJ
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
RNS
ROL
RPZ
SBG
SCB
SDF
SDG
SDP
SES
SEW
SIN
SOC
SPC
SPCBC
SPT
SSI
SSK
SSP
SSU
SSZ
T5K
UQL
WH7
WUQ
XPP
ZGI
ZMT
~G-
~KM
AATTM
AAXKI
AAYWO
AAYXX
ABWVN
ACLOT
ACRPL
ACVFH
ADCNI
ADNMO
AEIPS
AEUPX
AFJKZ
AFPUW
AGQPQ
AIGII
AIIUN
AKBMS
AKRWK
AKYEP
ANKPU
APXCP
CITATION
EFKBS
~HD
BNPGV
CGR
CUY
CVF
ECM
EIF
NPM
SSH
7X8
ID FETCH-LOGICAL-c362t-4a1cac39bfb66ad7b39938d7285aed164db58e8352790136591d8f1a68c722563
IEDL.DBID .~1
ISSN 0045-2068
1090-2120
IngestDate Mon Sep 29 06:23:36 EDT 2025
Thu Apr 03 06:53:55 EDT 2025
Wed Oct 01 05:14:47 EDT 2025
Thu Apr 24 23:02:58 EDT 2025
Fri Feb 23 02:47:07 EST 2024
IsPeerReviewed true
IsScholarly true
Keywords DMSO
FLT3
Structure–activity relationship (SAR)
TFA
NF-κB
PI3K
GSK3
IC50
mTOR
NPY-Y5
CD38
WHO
DPPH
MIC
IL-2
Pharmacokinetic
SV2
SQS
APVM
PIP3
HCV
ERK
FDA
SAR
CK2
BASF
MCSF
PDK
BRD4
DNA-PK
ISO
ADME
EGF
IKK
Akt
Pharmacological profile
COX
ACP
TB
DHFR
Morpholine
HER
HIV
TNF-α
DNA
MAPK or MEK
PDGF
Raf
Pharmacophore
ATR
Language English
License Copyright © 2020 Elsevier Inc. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c362t-4a1cac39bfb66ad7b39938d7285aed164db58e8352790136591d8f1a68c722563
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
PMID 31978684
PQID 2345507781
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2345507781
pubmed_primary_31978684
crossref_citationtrail_10_1016_j_bioorg_2020_103578
crossref_primary_10_1016_j_bioorg_2020_103578
elsevier_sciencedirect_doi_10_1016_j_bioorg_2020_103578
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate March 2020
2020-03-00
20200301
PublicationDateYYYYMMDD 2020-03-01
PublicationDate_xml – month: 03
  year: 2020
  text: March 2020
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Bioorganic chemistry
PublicationTitleAlternate Bioorg Chem
PublicationYear 2020
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Deka, Indukuri, Sultana, Borah, Saikia (b0095) 2015; 80
Mardal, Miserez, Bade, Portolés, Bischoff, Hernández, Meyer (b0275) 2016; 128
Triest, Damstrup, Falkenius, Budach, Troost, Samuels, Debus, Sørensen, Berghoff, Strotman, Bussel, Goel, Geertsen (b1190) 2018; 36
Lisi, Aceto, Navarra, Dello Russo (b1160) 2015
Kravchenko, Kysil, Tkachenko, Maliarchouk, Okun, Ivachtchenko (b0485) 2005; 40
Castel, Toska, Zumsteg, Carmona, Elkabets, Bosch, Scaltriti (b0920) 2014; 1
Badawneh, Aljamal (b0785) 2016; 8
Liu, Wang, Jiang (b0490) 2015; 35
Shinohara, Geng, Tan, Chen, Shir, Edwards, Halbrook, Kesicki, Kashishian, Hallahan (b0905) 2005; 65
Sehajpal, Prasad, Singh (b0635) 2018; 18
Kumar, Thakur, Sharma, Bhardwaj, Singh (b0540) 2019; 53
Malagu, Duggan, Menear, Hummersone, Gomez, Bailey, Edwards, Drzewiecki, Leroux, Quesada, Hermann, Maine, Molyneaux, Le Gall, Pullen, Hickson, Smith, Maguire, Martin, Smith, Pass (b1110) 2009; 19
Härtter, Dingemanse, Baier (b0295) 1996; 6
Pieniaszek, Davidson, Chaney, Shum, Robinson, Mayersohn (b0270) 1999; 29
US patent 2943022, H. Siemer, A. Doppstadt, Substituted 1-phenyl-2,3-dimethyl-4-morpholino methyl pyrazolone-(5) compounds and process of making same, issued 1960-06-28, assigned to Ravensberg.
Vlahos, Matter, Hui, Brown (b0835) 1994; 269
Matralis, Kourounakis (b0605) 2018; 10
Martínez González, Hernández, Varela, Lorenzo, Ramos Lima, Cendón, Cebrián, Aguirre, Gomez-Casero, Albarrán, Alfonso, García-Serelde, Mateos, Oyarzabal, Rabal, Mulero, Gonzalez-Granda, Link, Fominaya, Barbacid, Bischoff, Pizcueta, Blanco-Aparicio, Pastor (b1030) 2010; 9
Wang, Qiu, Maa, Yan, Gong, Wang, Zhu (b0705) 2015; 5
Wang, Xin, Xu, Kang, Li, Lu, Zhang (b0440) 2015; 96
Khan, Khan, Taha, Maharvi, Saify, Parveen, Choudhary (b0825) 2009; 23
Willems, Chapuis, Puissant, Maciel, Green, Jacque, Vignon, Park, Guichard, Herault, Fricot, Hermine, Moura, Auberger, Ifrah, Dreyfus, Bonnet, Lacombe, Mayeux, Bouscary, Tamburini (b1115) 2012; 26
Chandra, Alexander, Lee, Jeong (b0895) 2012; 35
Wu, Lu, Yan, Tang, Sun, Liu, Zhou, Yang (b0480) 2014; 22
Munck, Batey, Zhao, Jenkins, Richardson, Cano, Tavecchio, Barbeau, Bardos, Cornell, Griffin, Menear, Slade, Thommes, Martin, Newell, Smith, Curtin (b0880) 2010; 11
Nelson, Fraunfelder, Sills, Arrowsmith, Kuritsky (b0145) 1986; 102
.
Shcherbatiuk, Shyshlyk, Yarmoliuk, Shishkin, Shishkina, Starova, Zaporozhets, Zozulya, Moriev, Kravchuk, Manoilenko, Tolmachev, Mykhailiuk (b0325) 2013; 69
Kumari, Singh (b0010) 2019; 89
Jackson, Schoenwaelder, Goncalves, Nesbitt, Yap, Wright, Kenche, Anderson, Dopheide, Yuan, Sturgeon, Prabaharan, Thompson, Smith, Shepherd, Daniele, Kulkarni, Abbott, Saylik, Jones, Lu, Giuliano, Hughan, Angus, Robertson, Salem (b0940) 2005; 11
Nutley, Smith, Hayes, Kelland, Brunton, Golding, Smith, Martin, Workman, Raynaud (b0855) 2005; 93
Lu, Stahl (b0105) 2012; 14
Kerkenaar (b0675) 1987
Vandel, Vandel, Jounet, Blum (b0290) 1982; 7
Gallo-Ebert, Donigan, Stroke, Swanson, Manners, Francisco, Toner, Gallagher, Huang, Gygax, Webb, Nickels (b0190) 2014; 58
Chwastek, Jantas, Lasoń (b0865) 2017; 87
Can, Çevik, Sağlık, Özkay, Atlı, Baysal, Özkay, Can (b0700) 2017; 22
Djuzenova, Fiedler, Katzer, Michel, Deckert, Zimmermann, Sukhorukov, Flentje (b0980) 2016; 7
Guichard, Curwen, Bihani, D'Cruz, Yates, Grondine, Howard, Davies, Bigley, Klinowska, Pike, Pass, Chresta, Polanska, McEwen, Delpuech, Green, Cosulich (b1130) 2015; 14
Sanchez, Wang, Newton, Bakhtiar, Lu, Chiu, Evans, Huskey, Larry, Cecilia, Michael, Michael (b0280) 2004; 32
Yancheva, Daskalova, Cherneva, Mikhova, Djordjevic, Smelcerovic, Smelcerovic (b0725) 2012; 1016
Zhao, Thomas, Batey, Cowell, Richardson, Griffin, Calvert, Newell, Smith, Curtin (b0850) 2016; 66
Rivero, Hardwicke (b0960) 2012
Nylander, Kull, Björkman, Ulvinge, Oakes, Emanuelsson, Andersson, Skärby, Inghardt, Fjellström, Gustafsson (b0945) 2012; 10
Hoesel, Schmid (b0495) 2013; 12
Kusano-Kitazume, Sakamoto, Okuno, Sekine-Osajima, Nakagawa, Kakinuma, Kiyohashi, Nitta, Murakawa, Azuma, Nishimura-Sakurai, Hagiwara, Watanabe (b0565) 2012; 56
Ghorbani, Farhoudi (b0810) 2017; 12
Tiberi, Muñoz-Torrico, Duarte, Dalcolmo, D'Ambrosio, Migliori (b0745) 2018; 24
Choi, Lee, Kim, Nam Shin, Chun (b0110) 2008; 29
Freitag, Christen, Lewens, Grass, Briest, Iwaszkiewicz, Siegmund, Grabowski (b1070) 2017; 105
Burland, Osborn, Turkson (b0040) 2011; 19
Keldenich, Michon, Nowicki, Agbossou Niedercorn (b0045) 2011
Wang, Kuramitsu, Baron, Kitagawa, Tokuda, Akada, Maehara, Maehara, Nakamura (b0830) 2017; 50
Rathore, Sudhakar, Ahsan, Ali, Subbarao, Jadav, Umar, Yar (b0510) 2013; 55
J. Buckingham (Ed.), Dictionary of Organic Compounds, 7. Chapman & Hall, London, 1996, p. 4659.
Süleymanoğlu, Ustabaş, Direkel, Alpaslan, Ünver (b0820) 2018; 96
Pulipati, Yogeeswari, Sriram, Kantevari (b0775) 2016; 26
Cerqueira, Oliveira, Gesto, Santos-Martins, Moreira, Moorthy, Ramos, Fernandes (b0585) 2016; 55
Matralis, Kourounakis (b0595) 2014; 57
Cross, Scheel-Toellner, Henriquez, Deacon, Salmon, Lord (b0400) 2000; 256
Blanco, Perez-Herran, Cacho, Ballell, Castro, del Río, Lavandera, Remuiñán, Richards, Rullas, Vázquez-Muñiz, Woldu, Zapatero-González, Angulo-Barturen, Mendoza, Barros (b0780) 2015; 59
file:///C:/Users/PEARL/Downloads/Asymmetric+Synthesis+of+2%252C2%E2%80%99-Bimorpholine+and+its+5%252C5%E2%80%99-Substituted+Derivatives%20(1).pdf.
Salles, Calsou, Frit, Muller (b0910) 2015; 54
Gursoy-Kol, Yuksek, Manap, Tokalı (b0620) 2016; 3
Begum, Khanum, Ranganatha, Prashanth, Al-Ghorbani, Khanum (b0715) 2010; 6
Tereshchenko, Myronchuk, Leitchenko, Knysh, Tokmakova, Litsis, Tolmachev, Liubchak, Mykhailiuk (b0235) 2017; 73
Scaltriti, Baselga (b0365) 2006; 22
Wuitschik, Rogers-Evans, Muller, Fischer, Wagner, Schuler, Polonchuk, Carreira (b0310) 2006; 45
Gomtsyan (b0005) 2012; 48
Knight, Chiang, Alaimo, Kenski, Ho, Coan, Abraham, Shokat (b0925) 2004; 12
Z. Shao, Q. Bao, F. Jiang, H. Qian, Q. Fang, X. Hu, VS-5584, a Novel PI3K-mTOR Dual inhibitor, inhibits melanoma cell growth in vitro and in vivo, PLoS One 23 (2015) 10(7):e0132655.
Groll, Piscitelli, Walsh (b0200) 1998; 44
Tesfaye, Ravichadran (b0340) 2018; 6
Park, Kim, Kim, Lee, Bae, Kim, Na, Yoon (b0505) 2017; 70
Hickson, Yan, Richardson, Green, Martin, Orr, Reaper, Jackson, Curtin, Smith (b0875) 2004; 64
G. Seyffart, Drug Dosage in Renal Insufficiency. Kluwer Academic Publishers, Boston (1991) 399 (retrieved on 02 February 2019).
E. Vitaku, D.T. Smith, J.T. Njardarson, Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals, J. Med. Chem. 57 (2014) 10257–10274.
H. Ren, X. Li, Z. H. Ni, J.Y. Niu, B. Cao, J. Xu, H. Cheng, X. W.Tu, A. M. Ren, Y. Hu, C.Y. Xing, Y.H. Liu, Y.F. Li, J. Cen, R. Zhou, X.D.; Xu, X.H. Qiu, N. Chen, Treatment of complicated urinary tract infection and acute pyelonephritis by short course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500mg/day): a prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial, Int. Urol. Nephrol. 49 (2017) 499–507.
McKillop, McCormick, Miles, Phillips, Pickup, Bushby, Hutchison (b0260) 2004; 34
Ladopoulou, Matralis, Nikitakis, Kourounakis (b0600) 2015; 23
Chresta, Davies, Hickson, Harding, Cosulich, Critchlow, Vincent, Ellston, Jones, Sini, James, Howard, Dudley, Hughes, Smith, Maguire, Hummersone, Malagu, Menear, Jenkins, Jacobsen, Smith, Guichard, Pass (b1125) 2010; 70
Ibrahim, Abou-Seri, Hanna, Abdalla, El Sayed (b0455) 2015; 99
FDA approves Xtoro to treat swimmer's ear. Food and Drug Administration, December 17, 2014 (accessed on 05 April 2019).
Andrs, Korabecny, Jun, Hodny, Bartek, Kuca (b0405) 2015; 58
Jackl, Legnani, Morandi, Bode (b0075) 2017; 19
Pushpak, Bekington (b0240) 2006; 47
Bédard, Davies, Kopetz, Juric, Shapiro, Luke, Spreafico, Wu, Castell, Gomez, Cartot-Cotton, Mazuir, Dubar, Micallef, Demers, Flaherty (b0970) 2018; 124
Ohwada, Ebiike, Kawada, Tsukazaki, Nakamura, Miyazaki, Morikami, Yoshinari, Yoshida, Kondoh, Kuramoto, Ogawa, Aoki, Shimma (b1090) 2011; 21
Shaikh, Zaheer, Mokale, Lokwani (b0770) 2017; 9
Lau, Zhai, Schafer (b0080) 2016; 81
Lin, Man, Santiago, Park, Roelandt, Oda, Hupe, Crumrine, Lee, Gschwandtner, Thyssen, Trullas, Tschachler, Feingold, Elias (b0520) 2013; 133
Volotinen, Turpeinen, Tolonen, Uusitalo, Mäenpää, Pelkonen (b0305) 2007; 35
Oliveira, Teixeira, Cassiano (b0695) 2016; 23
Martínez González, Hernández, Varela, Lorenzo, Ramos-Lima, Cendón, Cebrián, Aguirre, Gomez-Casero, Albarrán, Alfonso, García-Serelde, Mateos, Oyarzabal, Rabal, Mulero, Gonzalez-Granda, Link, Fominaya, Barbacid, Bischoff, Pizcueta, Blanco-Aparicio, Pastor (b1025) 2012; 22
Eyding, Lelgemann, Grouven, Härter, Kromp, Kaiser, Kerekes, Gerken, Wieseler (b0165) 2010; 341
Kumar, Singh, Bhardwaj (b0575) 2017; 85
Hollick, Rigoreau, Cano-Soumillac, Cockcroft, Curtin, Frigerio, Golding, Guiard, Hardcastle, Hickson, Hummersone, Menear, Martin, Matthews, Newell, Ord, Richardson, Smith, Griffin (b0870) 2007; 50
Raynaud, Eccles, Clarke, Hayes, Nutley, Alix, Henley, Di-Stefano, Ahmad, Guillard, Bjerke, Kelland, Valenti, Patterson, Gowan, Brandon, De, Hayakawa, Kaizawa, Koizumi, Ohishi, Patel, Saghir, Parker, Waterfield, Workman (b0985) 2007; 67
Yang, Guo, Stacey, Harwalkar, Fretthold, Hitomi, Stacey (b0360) 2006; 7
Ladopoulou, Matralis, Kourounakis (b0590) 2013; 56
Ghorbani, Begum, Mamatha, Khanum (b0135) 2015; 7
Bungard, Williams, Ballard, Bennett, Beaulieu, Bahnck-Teets, Carroll, Chang, Dubost, Fay, Diamond, Greshock, Hao, Holloway, Felock, Gesell, Su, Manikowski, McKay, Miller, Min, Molinaro, Moradei, Nantermet, Nadeau, Sanchez, Satyanarayana, Shipe, Singh, Truong, Vijayasaradhi, Wiscount, Vacca, Crane, McCauley (b0560) 2016; 7
Granda, Cebrián, Martínez, Anguita, López, Link, Merino, Pastor, Serelde, Peregrina, Palacios, Albarran, Cebriá, Lorenzo, Alonso, Fominaya, López, Bischoff (b1020) 2013; 31
Liu, Bailey, Dinh, Lam, Li, Wells, Yin, Zou (b1165) 2012; 22
Muhammad, Edrees, Faty, Gomha, Alterary, Mabkhot (b0420) 2017; 22
Mallon, Feldberg, Lucas, Chaud
Sanchez (10.1016/j.bioorg.2020.103578_b0280) 2004; 32
Choi (10.1016/j.bioorg.2020.103578_b0110) 2008; 29
Nutley (10.1016/j.bioorg.2020.103578_b0855) 2005; 93
Raynaud (10.1016/j.bioorg.2020.103578_b0985) 2007; 67
Nelson (10.1016/j.bioorg.2020.103578_b0145) 1986; 102
Shcherbatiuk (10.1016/j.bioorg.2020.103578_b0325) 2013; 69
Bloom (10.1016/j.bioorg.2020.103578_b0740) 2018; 379
10.1016/j.bioorg.2020.103578_b0175
Powles (10.1016/j.bioorg.2020.103578_b1010) 2016; 34
10.1016/j.bioorg.2020.103578_b0180
Vidhya (10.1016/j.bioorg.2020.103578_b0680) 2017; 9
Sun (10.1016/j.bioorg.2020.103578_b0060) 2009; 50
Pike (10.1016/j.bioorg.2020.103578_b1120) 2013; 23
Yancheva (10.1016/j.bioorg.2020.103578_b0725) 2012; 1016
Jackson (10.1016/j.bioorg.2020.103578_b0940) 2005; 11
Polak (10.1016/j.bioorg.2020.103578_b0670) 1988; 544
Vandel (10.1016/j.bioorg.2020.103578_b0290) 1982; 7
Malagu (10.1016/j.bioorg.2020.103578_b1110) 2009; 19
10.1016/j.bioorg.2020.103578_b0160
Aktar (10.1016/j.bioorg.2020.103578_b0415) 2018; 42
Smelcerovic (10.1016/j.bioorg.2020.103578_b0515) 2013; 55
Guichard (10.1016/j.bioorg.2020.103578_b1130) 2015; 14
Park (10.1016/j.bioorg.2020.103578_b0505) 2017; 70
Kumar (10.1016/j.bioorg.2020.103578_b0015) 2016; 14
Wuitschik (10.1016/j.bioorg.2020.103578_b0315) 2010; 53
Chwastek (10.1016/j.bioorg.2020.103578_b0865) 2017; 87
Durant (10.1016/j.bioorg.2020.103578_b0900) 2003; 31
10.1016/j.bioorg.2020.103578_b0170
Andrs (10.1016/j.bioorg.2020.103578_b0405) 2015; 58
Willems (10.1016/j.bioorg.2020.103578_b1115) 2012; 26
Yang (10.1016/j.bioorg.2020.103578_b0360) 2006; 7
Rivero (10.1016/j.bioorg.2020.103578_b0960) 2012
Meìtro (10.1016/j.bioorg.2020.103578_b0050) 2011; 76
10.1016/j.bioorg.2020.103578_b0755
Lin (10.1016/j.bioorg.2020.103578_b0520) 2013; 133
Singh (10.1016/j.bioorg.2020.103578_b1045) 2018; 149
10.1016/j.bioorg.2020.103578_b0195
Ahmadi (10.1016/j.bioorg.2020.103578_b0525) 2012; 21
Chandra (10.1016/j.bioorg.2020.103578_b0895) 2012; 35
Li (10.1016/j.bioorg.2020.103578_b1055) 2010; 334
Bédard (10.1016/j.bioorg.2020.103578_b0970) 2018; 124
Tan (10.1016/j.bioorg.2020.103578_b0610) 2018; 9
Kim (10.1016/j.bioorg.2020.103578_b0950) 2009; 284
Liu (10.1016/j.bioorg.2020.103578_b0395) 2009; 8
Nelson (10.1016/j.bioorg.2020.103578_b0065) 2004; 45
Blanco (10.1016/j.bioorg.2020.103578_b0780) 2015; 59
Hoesel (10.1016/j.bioorg.2020.103578_b0495) 2013; 12
Ladopoulou (10.1016/j.bioorg.2020.103578_b0600) 2015; 23
Fernandes (10.1016/j.bioorg.2020.103578_b0765) 2017; 10
Rewcastle (10.1016/j.bioorg.2020.103578_b0410) 2011; 54
Kourounakis (10.1016/j.bioorg.2020.103578_b0255) 2019
10.1016/j.bioorg.2020.103578_b0185
Gram (10.1016/j.bioorg.2020.103578_b0300) 1993; 35
Certal (10.1016/j.bioorg.2020.103578_b0975) 2014; 57
Wang (10.1016/j.bioorg.2020.103578_b0470) 2012; 3
Ladopoulou (10.1016/j.bioorg.2020.103578_b0590) 2013; 56
Vlahos (10.1016/j.bioorg.2020.103578_b0835) 1994; 269
Granda (10.1016/j.bioorg.2020.103578_b1020) 2013; 31
Zhang (10.1016/j.bioorg.2020.103578_b0385) 2017; 27
Pieniaszek (10.1016/j.bioorg.2020.103578_b0270) 1999; 29
Alnemri (10.1016/j.bioorg.2020.103578_b0475) 1996; 87
Eyding (10.1016/j.bioorg.2020.103578_b0165) 2010; 341
10.1016/j.bioorg.2020.103578_b0370
Knight (10.1016/j.bioorg.2020.103578_b0925) 2004; 12
Zheng (10.1016/j.bioorg.2020.103578_b0375) 2015; 7
Khanum (10.1016/j.bioorg.2020.103578_b0530) 2010; 6
Sutherlin (10.1016/j.bioorg.2020.103578_b1015) 2011; 54
Cerqueira (10.1016/j.bioorg.2020.103578_b0585) 2016; 55
Tiberi (10.1016/j.bioorg.2020.103578_b0745) 2018; 24
Basavaraja (10.1016/j.bioorg.2020.103578_b0730) 2010; 2
10.1016/j.bioorg.2020.103578_b0815
Scaltriti (10.1016/j.bioorg.2020.103578_b0365) 2006; 22
Hollick (10.1016/j.bioorg.2020.103578_b0870) 2007; 50
Salles (10.1016/j.bioorg.2020.103578_b0910) 2015; 54
Rebecca (10.1016/j.bioorg.2020.103578_b0350) 2018; 68
Gursoy-Kol (10.1016/j.bioorg.2020.103578_b0620) 2016; 3
Gallo-Ebert (10.1016/j.bioorg.2020.103578_b0190) 2014; 58
Shaikh (10.1016/j.bioorg.2020.103578_b0770) 2017; 9
Sakthikumar (10.1016/j.bioorg.2020.103578_b0625) 2018; 80
Wienkers (10.1016/j.bioorg.2020.103578_b0285) 1999; 27
Wenqing (10.1016/j.bioorg.2020.103578_b0840) 2012; 4
Gomtsyan (10.1016/j.bioorg.2020.103578_b0005) 2012; 48
Panneerselvam (10.1016/j.bioorg.2020.103578_b0735) 2005; 40
Yu (10.1016/j.bioorg.2020.103578_b1145) 2009; 69
Venkatesan (10.1016/j.bioorg.2020.103578_b1035) 2010; 20
da Silva (10.1016/j.bioorg.2020.103578_b0230) 2019; 24
Muhammad (10.1016/j.bioorg.2020.103578_b0420) 2017; 22
Wijtmans (10.1016/j.bioorg.2020.103578_b0225) 2004; 2004
Singh (10.1016/j.bioorg.2020.103578_b0345) 2018; 151
10.1016/j.bioorg.2020.103578_b0150
Foote (10.1016/j.bioorg.2020.103578_b1185) 2013; 56
Härtter (10.1016/j.bioorg.2020.103578_b0295) 1996; 6
Ianevski (10.1016/j.bioorg.2020.103578_b0550) 2018; 154
Triest (10.1016/j.bioorg.2020.103578_b1190) 2018; 36
Tesfaye (10.1016/j.bioorg.2020.103578_b0340) 2018; 6
Keldenich (10.1016/j.bioorg.2020.103578_b0045) 2011
Liu (10.1016/j.bioorg.2020.103578_b0490) 2015; 35
Sun (10.1016/j.bioorg.2020.103578_b0090) 2015; 11
Matralis (10.1016/j.bioorg.2020.103578_b0605) 2018; 10
Rathore (10.1016/j.bioorg.2020.103578_b0510) 2013; 55
10.1016/j.bioorg.2020.103578_b0025
Pal’ Chikov (10.1016/j.bioorg.2020.103578_b0070) 2013; 49
Matlock (10.1016/j.bioorg.2020.103578_b0085) 2015; 17
Khan (10.1016/j.bioorg.2020.103578_b0825) 2009; 23
Degorce (10.1016/j.bioorg.2020.103578_b0335) 2018; 61
Ahmadi (10.1016/j.bioorg.2020.103578_b0645) 2011; 98
Kashishian (10.1016/j.bioorg.2020.103578_b0915) 2003; 2
Lisi (10.1016/j.bioorg.2020.103578_b1160) 2015
Netland (10.1016/j.bioorg.2020.103578_b1060) 2016; 129
Volotinen (10.1016/j.bioorg.2020.103578_b0305) 2007; 35
Kumar (10.1016/j.bioorg.2020.103578_b0425) 2017; 27
Mendes (10.1016/j.bioorg.2020.103578_b0665) 2014; 17
Kirichok (10.1016/j.bioorg.2020.103578_b0330) 2018; 24
Wu (10.1016/j.bioorg.2020.103578_b0480) 2014; 22
Berndt (10.1016/j.bioorg.2020.103578_b1050) 2010; 6
Zhu (10.1016/j.bioorg.2020.103578_b0380) 2014; 22
Dieckmann (10.1016/j.bioorg.2020.103578_b0035) 1993; 345
McKillop (10.1016/j.bioorg.2020.103578_b0260) 2004; 34
10.1016/j.bioorg.2020.103578_b0570
10.1016/j.bioorg.2020.103578_b0690
Rageot (10.1016/j.bioorg.2020.103578_b1195) 2018; 61
10.1016/j.bioorg.2020.103578_b0210
Kerkenaar (10.1016/j.bioorg.2020.103578_b0675) 1987
Lu (10.1016/j.bioorg.2020.103578_b0105) 2012; 14
Hickson (10.1016/j.bioorg.2020.103578_b0875) 2004; 64
Zhu (10.1016/j.bioorg.2020.103578_b0460) 2014; 22
Oliveira (10.1016/j.bioorg.2020.103578_b0695) 2016; 23
10.1016/j.bioorg.2020.103578_b0445
Wuitschik (10.1016/j.bioorg.2020.103578_b0320) 2008; 47
Bektaş (10.1016/j.bioorg.2020.103578_b0720) 2013; 22
Pulipati (10.1016/j.bioorg.2020.103578_b0775) 2016; 26
Thomas (10.1016/j.bioorg.2020.103578_b0790) 2014; 4
Rundle (10.1016/j.bioorg.2020.103578_b1180) 2017; 9
10.1016/j.bioorg.2020.103578_b1095
Somei (10.1016/j.bioorg.2020.103578_b0120) 1995; 41
Lundgren (10.1016/j.bioorg.2020.103578_b0630) 2017; 17
Castel (10.1016/j.bioorg.2020.103578_b0920) 2014; 1
Mallon (10.1016/j.bioorg.2020.103578_b1075) 2011; 17
Seelolla (10.1016/j.bioorg.2020.103578_b0710) 2014; 4
Martínez González (10.1016/j.bioorg.2020.103578_b1025) 2012; 22
Shappley (10.1016/j.bioorg.2020.103578_b1105) 2014; 2014
Mazu (10.1016/j.bioorg.2020.103578_b0205) 2016; 16
Zhao (10.1016/j.bioorg.2020.103578_b0850) 2016; 66
10.1016/j.bioorg.2020.103578_b0355
Martelli (10.1016/j.bioorg.2020.103578_b1170) 2018; 132
Garlich (10.1016/j.bioorg.2020.103578_b0845) 2008; 68
Ohwada (10.1016/j.bioorg.2020.103578_b1090) 2011; 21
Doan (10.1016/j.bioorg.2020.103578_b0430) 2016; 120
Tereshchenko (10.1016/j.bioorg.2020.103578_b0235) 2017; 73
Ibrahim (10.1016/j.bioorg.2020.103578_b0455) 2015; 99
Burland (10.1016/j.bioorg.2020.103578_b0040) 2011; 19
Cross (10.1016/j.bioorg.2020.103578_b0400) 2000; 256
Zask (10.1016/j.bioorg.2020.103578_b1155) 2009; 52
Zhou (10.1016/j.bioorg.2020.103578_b0245) 2014; 5
Pan (10.1016/j.bioorg.2020.103578_b1150) 2017; 12
Kumar (10.1016/j.bioorg.2020.103578_b0540) 2019; 53
Yao (10.1016/j.bioorg.2020.103578_b0100) 2015; 2
Schöffski (10.1016/j.bioorg.2020.103578_b0990) 2018; 20
Blagden (10.1016/j.bioorg.2020.103578_b1085) 2014; 20
Pratiksha (10.1016/j.bioorg.2020.103578_b0465) 2015; 5
Süleymanoğlu (10.1016/j.bioorg.2020.103578_b0820) 2018; 96
Martínez González (10.1016/j.bioorg.2020.103578_b1030) 2010; 9
Mallon (10.1016/j.bioorg.2020.103578_b1040) 2010; 9
Mateo (10.1016/j.bioorg.2020.103578_b0955) 2017; 23
Lau (10.1016/j.bioorg.2020.103578_b0080) 2016; 81
10.1016/j.bioorg.2020.103578_b0220
Slatter (10.1016/j.bioorg.2020.103578_b0265) 2009; 29
Rakesh (10.1016/j.bioorg.2020.103578_b0795) 2012; 20
Lukas (10.1016/j.bioorg.2020.103578_b0055) 2010; 53
Vecchio (10.1016/j.bioorg.2020.103578_b0890) 2013; 135
Burger (10.1016/j.bioorg.2020.103578_b1065) 2011; 2
Wuitschik (10.1016/j.bioorg.2020.103578_b0310) 2006; 45
Munck (10.1016/j.bioorg.2020.103578_b0880) 2010; 11
Liu (10.1016/j.bioorg.2020.103578_b1165) 2012; 22
Freitag (10.1016/j.bioorg.2020.103578_b1070) 2017; 105
Calcabrini (10.1016/j.bioorg.2020.103578_b0130) 2017; 15
Badawneh (10.1016/j.bioorg.2020.103578_b0785) 2016; 8
Wang (10.1016/j.bioorg.2020.103578_b0830) 2017; 50
Pushpak (10.1016/j.bioorg.2020.103578_b0240) 2006; 47
10.1016/j.bioorg.2020.103578_b0655
Bungard (10.1016/j.bioorg.2020.103578_b0560) 2016; 7
Bi (10.1016/j.bioorg.2020.103578_b0805) 2018; 2018
Arshad (10.1016/j.bioorg.2020.103578_b0250) 2019; 167
10.1016/j.bioorg.2020.103578_b0535
Tabbi (10.1016/j.bioorg.2020.103578_b0650) 2016; 40
Suntornchashwej (10.1016/j.bioorg.2020.103578_b0125) 2005; 68
Gharpure (10.1016/j.bioorg.2020.103578_b0030) 2011; 76
Kumar (10.1016/j.bioorg.2020.103578_b0575) 2017; 85
Venkatesan (10.1016/j.bioorg.2020.103578_b1080) 2010; 20
Heffron (10.1016/j.bioorg.2020.103578_b1005) 2010; 20
Hart (10.1016/j.bioorg.2020.103578_b1100) 2013; 12
Achari (10.1016/j.bioorg.2020.103578_b0020) 2014; 14
Kravchenko (10.1016/j.bioorg.2020.103578_b0485) 2005; 40
Shinohara (10.1016/j.bioorg.2020.103578_b0905) 2005; 65
Deka (10.1016/j.bioorg.2020.103578_b0095) 2015; 80
Abdelaziz (10.1016/j.bioorg.2020.103578_b0435) 2015; 5
Zhou (10.1016/j.bioorg.2020.103578_b1135) 2012; 31
Fekete (10.101
References_xml – reference: G.A. Kennett, P.G. AClifton, New approaches to the pharmacological treatment of obesity: can they break through the efficacy barrier? Pharmacol. Biochem. Behav. 97 (2010) 63–83.
– volume: 6
  start-page: 60
  year: 2010
  end-page: 65
  ident: b0530
  article-title: Synthesis of benzophenone-n-ethyl morpholine ethers as anti-inflammatory agents
  publication-title: Int. J. Biomed. Sci.
– volume: 22
  start-page: 5114
  year: 2012
  end-page: 5117
  ident: b1165
  article-title: Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors
  publication-title: Bioorg. Med. Chem. Lett.
– reference: G. Seyffart, Drug Dosage in Renal Insufficiency. Kluwer Academic Publishers, Boston (1991) 399 (retrieved on 02 February 2019).
– volume: 76
  start-page: 10325
  year: 2011
  end-page: 10331
  ident: b0030
  article-title: Stereoselective synthesis of C-substituted morpholine derivatives using reductive etherification reaction: total synthesis of chelonin C
  publication-title: J. Org. Chem.
– volume: 87
  start-page: 171
  year: 1996
  ident: b0475
  article-title: Human ICE/CED-3 protease nomenclature
  publication-title: Cell
– volume: 20
  start-page: 2408
  year: 2010
  end-page: 2411
  ident: b1000
  article-title: Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 6
  start-page: 225
  year: 1996
  end-page: 230
  ident: b0295
  article-title: The role of cytochrome P450 2D6 in the metabolism of moclobemide
  publication-title: Eur. Neuropsychopharmacol.
– volume: 45
  start-page: 5406
  year: 2002
  end-page: 5409
  ident: b0580
  article-title: Nitric oxide-releasing morpholine derivatives as hypolipidemic and antioxidant agents
  publication-title: J. Med. Chem.
– volume: 36
  start-page: 2518
  year: 2018
  ident: b1190
  article-title: A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: dose-escalation results
  publication-title: J. Clin. Onco.
– volume: 10
  start-page: 98
  year: 2018
  end-page: 104
  ident: b0605
  article-title: Optimizing the pharmacological profile of new bifunctional antihyperlipidemic/antioxidant morpholine derivatives
  publication-title: ACS Med. Chem. Lett.
– volume: 379
  start-page: 1672
  year: 2018
  end-page: 1674
  ident: b0740
  article-title: New promise for vaccines against tuberculosis
  publication-title: N. Engl. J. Med.
– volume: 68
  start-page: 206
  year: 2008
  end-page: 215
  ident: b0845
  article-title: Vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity
  publication-title: Cancer Res.
– volume: 22
  start-page: 613
  year: 2017
  ident: b0450
  article-title: Synthesis of pyrrolo[1,2-a]pyrimidine enantiomers
  publication-title: Molecules
– volume: 22
  start-page: 5208
  year: 2012
  end-page: 5214
  ident: b1025
  article-title: Rapid Identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 81
  start-page: 8696
  year: 2016
  end-page: 8709
  ident: b0080
  article-title: Catalytic asymmetric synthesis of morpholines using mechanistic insights to realize the enantioselective synthesis of piperazines
  publication-title: J. Org. Chem.
– volume: 44
  start-page: 343
  year: 1998
  end-page: 500
  ident: b0200
  article-title: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds and putative targets for antifungal drug development
  publication-title: Adv. Pharmacol.
– volume: 7
  start-page: 65
  year: 1982
  end-page: 68
  ident: b0290
  article-title: Pharmacokinetics of viloxazine hydrochloride in man
  publication-title: Eur. J. Drug Metab. Pharmacokinet.
– volume: 54
  start-page: 7579
  year: 2011
  end-page: 7587
  ident: b1015
  article-title: Discovery of a potent, selective, and orally available class i phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mtor) kinase inhibitor (GDC-0980) for the treatment of cancer
  publication-title: J. Med. Chem.
– volume: 55
  start-page: 5483
  year: 2016
  end-page: 5506
  ident: b0585
  article-title: Cholesterol biosynthesis: a mechanistic overview
  publication-title: Biochemistry
– volume: 24
  start-page: 86
  year: 2018
  end-page: 98
  ident: b0745
  article-title: New drugs and perspectives for new anti-tuberculosis regimens
  publication-title: Pulmonology
– volume: 23
  start-page: 5981
  year: 2017
  end-page: 5992
  ident: b0955
  article-title: The first-time-in-human study of gsk2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumours
  publication-title: Clin. Cancer Res.
– volume: 31
  start-page: 66
  year: 2013
  end-page: 76
  ident: b1020
  article-title: Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases
  publication-title: Invest. New Drugs
– volume: 6
  start-page: 117
  year: 2010
  end-page: 124
  ident: b1050
  article-title: The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
  publication-title: Nat. Chem. Biol.
– volume: 84
  start-page: 255
  year: 2016
  end-page: 268
  ident: b0215
  article-title: Synthesis and biological activity of new [1,3]thiazolo[4,5-
  publication-title: Sci. Pharm.
– volume: 66
  start-page: 5354
  year: 2016
  end-page: 5362
  ident: b0850
  article-title: Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441
  publication-title: Cancer Res.
– volume: 9
  start-page: 146
  year: 2017
  end-page: 158
  ident: b0685
  article-title: Synthesis and evaluation of the biological activity of new 4-(2-chloroacetyl) morpholine
  publication-title: J. Chem. Pharm. Res.
– volume: 149
  start-page: 387
  year: 2018
  end-page: 393
  ident: b1045
  article-title: Determination of ZSTK474, a novel Pan PI3K inhibitor in mouse plasma by LC-MS/MS and its application to Pharmacokinetics
  publication-title: J. Pharm. Biomed. Anal.
– volume: 53
  start-page: 3227
  year: 2010
  ident: b0315
  article-title: Oxetanes in drug discovery: structural and synthetic insights
  publication-title: J. Med. Chem.
– volume: 11
  start-page: 524
  year: 2015
  end-page: 529
  ident: b0090
  article-title: Metal-free one-pot synthesis of 2-substituted and 2,3-disubstituted morpholines from aziridines
  publication-title: Beilstein J. Org. Chem.
– volume: 6
  start-page: 31
  year: 2017
  end-page: 68
  ident: b0155
  article-title: Monoamine oxidase inhibitors—revisiting a therapeutic principle
  publication-title: Open J. Depress.
– volume: 22
  start-page: 2416
  year: 2014
  end-page: 2426
  ident: b0480
  article-title: 1,2-benzisothiazol-3-one derivatives as a novel class of small-molecule caspase-3 inhibitors
  publication-title: Bioorg. Med. Chem.
– volume: 53
  start-page: 4731
  year: 2010
  end-page: 4748
  ident: b0055
  article-title: Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation
  publication-title: J. Med. Chem.
– volume: 1
  year: 2014
  ident: b0920
  article-title: Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment
  publication-title: Mol. Cell Oncol.
– volume: 34
  start-page: 983
  year: 2004
  end-page: 1000
  ident: b0260
  article-title: In vitro metabolism of gefitinib in human liver microsomes
  publication-title: Xenobiotica
– volume: 12
  year: 2017
  ident: b1150
  article-title: Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo
  publication-title: PLoS ONE
– volume: 85
  start-page: 182
  year: 2017
  end-page: 201
  ident: b0575
  article-title: Therapeutic role of nitric oxide as emerging molecules
  publication-title: Biomed. Pharmacother.
– volume: 96
  start-page: 382
  year: 2015
  end-page: 395
  ident: b0440
  article-title: Synthesis and antitumor activities evaluation of
  publication-title: Eur. J. Med. Chem.
– volume: 68
  start-page: 951
  year: 2005
  end-page: 955
  ident: b0125
  article-title: Hectochlorin and morpholine derivatives from the Thai sea hare,
  publication-title: J. Nat. Prod.
– volume: 61
  start-page: 8934
  year: 2018
  end-page: 8943
  ident: b0335
  article-title: Lowering lipophilicity by adding carbon: one-carbon bridges of morpholines and piperazines
  publication-title: J. Med. Chem.
– reference: L.A.T. Cleghorn, P.C. Ray, J. Odingo, A. Kumar, H. Wescott, A. Korkegian, T. Masquelin, A. Lopez Moure A, C. Wilson, S. Davis, M. Huggett, P. Turner, A. Smith, O. Epemolu, F. Zuccotto, J. Riley, P. Scullion, Y. Shishikura, L. Ferguson, J. Rullas, L. Guijarro, K.D. Read, S.R. Green, P. Hipskind, T. Parish, P.G. Wyatt, Identification of morpholino thiophenes as novel mycobacterium tuberculosis inhibitors, targeting QcrB, 2 J. Med. Chem. 61 (2018) 6592–6608.
– volume: 20
  start-page: 450
  year: 2015
  end-page: 458
  ident: b0140
  article-title: Aprepitant and fosaprepitant: a 10-year review of efficacy and safety
  publication-title: Oncologist
– volume: 544
  start-page: 221
  year: 1988
  end-page: 228
  ident: b0670
  article-title: Mode of action of morpholine derivatives
  publication-title: Ann. N. Y. Acad. Sci.
– reference: R. Kumar, S. Kapur, The biodegradation of environmental pollutant –“Morpholine”, National Conference on “Biodiversity, Environment Hazards – Therapeutic approaches and Drug Design“ at Government Degree College for Women, Srikalahasthi, Andhra Pradesh, 26–27th, July 2014 (retrieved on 12 April 2019).
– volume: 9
  year: 2017
  ident: b1180
  article-title: Targeting the ATR-CHK1 axis in cancer therapy
  publication-title: Cancers (Basel)
– volume: 26
  start-page: 2649
  year: 2016
  end-page: 2654
  ident: b0775
  article-title: Click-based synthesis and antitubercular evaluation of novel dibenzo[b, d]thiophene-1,2,3-triazoles with piperidine, piperazine, morpholine and thiomorpholine appendages
  publication-title: Bioorg. Med. Chem. Lett.
– reference: J. Buckingham (Ed.), Dictionary of Organic Compounds, 7. Chapman & Hall, London, 1996, p. 4659.
– volume: 8
  start-page: 252
  year: 2016
  end-page: 257
  ident: b0785
  article-title: Synthesis and antitubercular activity of piperidine and morpholine 1, 8 naphthyridine analogues
  publication-title: Int. J. Pharm. Pharm. Sci.
– volume: 54
  start-page: 185
  year: 2015
  end-page: 193
  ident: b0910
  article-title: The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy
  publication-title: Pathol. Biol. (Paris)
– volume: 23
  start-page: 34
  year: 2016
  end-page: 38
  ident: b0695
  article-title: Modulation of the antibiotic activity against multidrug resistant strains of 4-(phenylsulfonyl) morpholine
  publication-title: Saudi.J Biol. Sci.
– volume: 56
  start-page: 2125
  year: 2013
  end-page: 2138
  ident: b1185
  article-title: Discovery of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1h-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity
  publication-title: J. Med. Chem.
– volume: 80
  start-page: 727
  year: 2018
  end-page: 738
  ident: b0625
  article-title: Antimicrobial, antioxidant and DNA interaction studies of water-soluble complexes of Schiff base bearing morpholine moiety
  publication-title: Indian J. Pharm. Sci.
– volume: 22
  start-page: 1374
  year: 2017
  ident: b0700
  article-title: Pharmacological and toxicological screening of novel benzimidazole-morpholine derivatives as dual-acting inhibitors
  publication-title: Molecules
– reference: FDA approves Xtoro to treat swimmer's ear. Food and Drug Administration, December 17, 2014 (accessed on 05 April 2019).
– volume: 65
  start-page: 4987
  year: 2005
  end-page: 4992
  ident: b0905
  article-title: DNA-dependent protein kinase is a molecular target for the development of non-cytotoxic radiation-sensitizing drugs
  publication-title: Cancer Res.
– year: 2015
  ident: b1160
  article-title: mTOR kinase: a possible pharmacological target in the management of chronic pain
  publication-title: Biomed. Res. Int.
– volume: 7
  start-page: 281
  year: 2015
  end-page: 301
  ident: b0135
  article-title: Piperazine and morpholine: synthetic preview and pharmaceutical applications
  publication-title: J. Chem. Pharm. Res.
– volume: 29
  start-page: 1443
  year: 2008
  end-page: 1444
  ident: b0110
  article-title: Preparation of morpholine-2-one and 1,4-oxazepan-2-one derivatives by cyclization reaction between N-Bts amino alcohol and chloroacetyl chloride
  publication-title: Bull. Korean Chem. Soc.
– volume: 11
  start-page: 507
  year: 2005
  end-page: 514
  ident: b0940
  article-title: PI 3-kinase p110beta: a new target for antithrombotic therapy
  publication-title: Nat. Med.
– volume: 42
  start-page: 482
  year: 2018
  end-page: 492
  ident: b0415
  article-title: Synthesis and biological evaluation of novel chalcones bearing morpholine moiety as antiproliferative agents
  publication-title: Turk. J. Chem.
– volume: 22
  start-page: 6746
  year: 2014
  end-page: 6754
  ident: b0380
  article-title: Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5
  publication-title: Bioorg. Med. Chem.
– volume: 128
  start-page: 485
  year: 2016
  end-page: 495
  ident: b0275
  article-title: 3-Fluorophenmetrazine, a fluorinated analogue of phenmetrazine: studies on in vivo metabolism in rat and human, in vitro metabolism in human CYP isoenzymes and microbial biotransformation in Pseudomonas Putida and wastewater using GC and LC coupled to (HR)-MS techniques
  publication-title: J. Pharm. Biomed. Anal.
– volume: 341
  start-page: 4737
  year: 2010
  ident: b0165
  article-title: Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
  publication-title: BMJ
– volume: 22
  start-page: 3629
  year: 2013
  end-page: 3639
  ident: b0720
  article-title: Antimicrobial and antiurease activities of newly synthesized morpholine derivatives containingan azole nucleus
  publication-title: Med. Chem. Res.
– volume: 61
  start-page: 10084
  year: 2018
  end-page: 10105
  ident: b1195
  article-title: Discovery and preclinical characterization of 5–[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a highly potent and selective mTORC1/2 inhibitor for cancer and neurological disorders
  publication-title: J. Med. Chem.
– volume: 16
  start-page: 555
  year: 2016
  end-page: 578
  ident: b0205
  article-title: The mechanistic targets of antifungal agents: an overview
  publication-title: Mini Rev. Med. Chem.
– volume: 9
  start-page: 55
  year: 2017
  end-page: 59
  ident: b0680
  article-title: Synthesis, characterization and antimicrobial evaluation of novel 2-pyrazoline derivatives containing morpholine moiety
  publication-title: Der. Pharmacia. Lett.
– volume: 2
  start-page: 721
  year: 2015
  end-page: 725
  ident: b0100
  article-title: Synthesis of morpholine or piperazine derivatives through gold-catalyzed cyclization reactions of alkynylamines or alkynylalcohols
  publication-title: Org. Chem. Front.
– volume: 5
  start-page: 253
  year: 2015
  end-page: 260
  ident: b0435
  article-title: Synthesis and evaluation of 5-chloro-2-methoxy-
  publication-title: Med. Chem.
– volume: 20
  start-page: 109
  year: 2018
  ident: b0990
  article-title: A phase Ib study of Pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
  publication-title: Breast Cancer Res.
– year: 2019
  ident: b0255
  article-title: Morpholine as a privileged structure: a review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules
  publication-title: Med. Res. Rev.
– reference: P. Panneerselvam, M. Gnanarupa Priya, N. Ramesh Kumar, G. Saravanan, Synthesis and pharmacological evaluation of Schiff bases of 4-(2-aminophenyl)-morpholines, Indian J. Pharm. Sci. 71(2009) 428–432.
– volume: 56
  start-page: 3330
  year: 2013
  end-page: 3338
  ident: b0590
  article-title: New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz) oxazine derivatives with antioxidant, anti hyperlipidemic, and antidiabetic action
  publication-title: J. Med. Chem.
– volume: 57
  start-page: 2568
  year: 2014
  end-page: 2581
  ident: b0595
  article-title: Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity
  publication-title: J. Med. Chem.
– volume: 53
  start-page: 343
  year: 2019
  end-page: 354
  ident: b0540
  article-title: Recent advances in the vaccines development for the treatment of emerging infectious diseases
  publication-title: Ind. J. Pharm. Edu. Res.
– volume: 151
  start-page: 401
  year: 2018
  end-page: 433
  ident: b0345
  article-title: Therapeutic journey of nitrogen mustard as alkylating anticancer agents: historic to future perspectives
  publication-title: Eur. J. Med. Chem.
– volume: 93
  start-page: 1011
  year: 2005
  end-page: 1018
  ident: b0855
  article-title: Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
  publication-title: Br. J. Cancer
– volume: 20
  start-page: 2408
  year: 2010
  end-page: 2411
  ident: b1005
  article-title: Identification of GNE-477, a potent and efficacious dual pi3k/mtor inhibitor
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 53
  start-page: 2025
  year: 1997
  end-page: 2028
  ident: b0115
  article-title: Polygonapholine, an alkaloid with a novel skeleton, isolated from polygonatum alte-lobatum
  publication-title: Tetrahedron
– volume: 69
  start-page: 3796
  year: 2013
  end-page: 3804
  ident: b0325
  article-title: Synthesis of 2- and 3-trifluoromethylmorpholines: useful building blocks for drug discovery
  publication-title: Tetrahedron
– volume: 17
  start-page: 1
  year: 2014
  end-page: 12
  ident: b0665
  article-title: Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms
  publication-title: Drug Resist. Updat.
– volume: 31
  start-page: 8
  year: 2012
  end-page: 18
  ident: b1135
  article-title: Current development of the second generation of mTOR inhibitors as anticancer agents
  publication-title: Chin. J. Cancer
– volume: 4
  start-page: 207
  year: 2012
  end-page: 213
  ident: b0840
  article-title: SF1126, a Pan-PI3K inhibitor has potent pre-clinical activity in aggressive B-cell non-Hodgkin lymphomas by inducing cell cycle arrest and apoptosis
  publication-title: J. Cancer Sci. Ther.
– volume: 3
  start-page: 373
  year: 2012
  end-page: 376
  ident: b0470
  article-title: URD12: a urea derivative with marked antitumor activities
  publication-title: Oncol. Lett.
– volume: 34
  start-page: 1660
  year: 2016
  end-page: 1668
  ident: b1010
  article-title: Randomized open-label phase II trial of Apitolisib (GDC-0980), a novel inhibitor of the PI3k/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma
  publication-title: J. Clin. Oncol.
– volume: 29
  start-page: 1136
  year: 2009
  end-page: 1145
  ident: b0265
  article-title: “Pharmacokinetics metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects
  publication-title: Drug Metab. Dispos.
– volume: 284
  start-page: 33763
  year: 2009
  end-page: 33772
  ident: b0950
  article-title: Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets
  publication-title: J. Biol. Chem.
– volume: 29
  start-page: 945
  year: 1999
  end-page: 955
  ident: b0270
  article-title: Human moricizine metabolism. II. Quantification and pharmacokinetics of plasma and urinary metabolites
  publication-title: Xenobiotica
– volume: 69
  start-page: 6232
  year: 2009
  end-page: 6240
  ident: b1145
  article-title: Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of Rapamycin
  publication-title: Cancer Res.
– volume: 96
  start-page: 719
  year: 2018
  end-page: 723
  ident: b0820
  article-title: 1,2,4-triazole derivatives with morpholine; DFT study and antileishmanial activity
  publication-title: Canadian J. Phys.
– volume: 19
  start-page: 4696
  year: 2017
  end-page: 4699
  ident: b0075
  article-title: Continuous flow synthesis of morpholines and oxazepanes with silicon amine protocol (slap) reagents and Lewis acid facilitated photoredox catalysis
  publication-title: Org. Lett.
– volume: 22
  start-page: 5268
  year: 2006
  end-page: 5272
  ident: b0365
  article-title: The epidermal growth factor receptor pathway: a model for targeted therapy
  publication-title: Clin Cancer Res.
– volume: 7
  start-page: 38191
  year: 2016
  end-page: 38209
  ident: b0980
  article-title: Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: the role of drug-irradiation schedule
  publication-title: Oncotarget
– volume: 24
  start-page: 5444
  year: 2018
  end-page: 5449
  ident: b0330
  article-title: Synthesis of multifunctional spirocyclic azetidines and their application in drug discovery
  publication-title: Chemistry
– volume: 47
  start-page: 7823
  year: 2006
  end-page: 7826
  ident: b0240
  article-title: Synthesis of substituted 4-(3-alkyl-1, 2, 4-oxadiazol-5-yl methyl)-3,4-dihydro-
  publication-title: Tetrahedron Lett.
– volume: 51
  start-page: 5522
  year: 2008
  end-page: 5532
  ident: b0995
  article-title: The identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
  publication-title: J. Med. Chem.
– volume: 103
  start-page: 4659
  year: 2004
  end-page: 4665
  ident: b0860
  article-title: A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia
  publication-title: Blood
– volume: 35
  start-page: 649
  year: 1993
  end-page: 652
  ident: b0300
  article-title: Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group
  publication-title: Br. J. Clin. Pharmacol.
– volume: 4
  start-page: 351
  year: 2014
  end-page: 359
  ident: b0790
  article-title: Novel Mannich bases of 4-thiazolidinon derivatives as antitubercular agents
  publication-title: IJRPC
– volume: 105
  start-page: 90
  year: 2017
  end-page: 104
  ident: b1070
  article-title: Inhibition of mTOR's catalytic site by pki-587 is a promising therapeutic option for gastro entero pancreatic neuroendocrine tumor disease
  publication-title: Neuroendocrinology
– volume: 8
  start-page: 627
  year: 2009
  end-page: 644
  ident: b0395
  article-title: Targeting the phosphoinositide 3-kinase pathway in cancer
  publication-title: Nat Rev Drug Discov.
– volume: 10
  year: 2017
  ident: b0765
  article-title: Advances in drug discovery of new antitubercular multidrug-resistant compounds
  publication-title: Pharmaceuticals (Basel)
– volume: 48
  start-page: 7
  year: 2012
  end-page: 10
  ident: b0005
  article-title: Heterocycles in drugs and drug discovery
  publication-title: Chem. Heterocycl. Compd.
– volume: 40
  start-page: 641
  year: 2016
  end-page: 654
  ident: b0650
  article-title: Synthesis of novel thiazolylpyrazoline derivatives and evaluation of their antimicrobial activities and cytotoxicities
  publication-title: Turk. J. Chem.
– volume: 35
  start-page: 1109
  year: 2015
  end-page: 1118
  ident: b0490
  article-title: Inflammation: the common pathway of stress-related diseases
  publication-title: Int. J. Mol. Med.
– reference: C.H. Takimoto, E. Calvo, Principles of oncologic pharmacotherapy, in: R. Pazdur, L.D. Wagman, K.A. Camphausen, W.J. Hoskins (Eds.), Cancer Management: A Multidisciplinary Approach, 11 ed., 2008.
– volume: 15
  start-page: 310
  year: 2017
  ident: b0130
  article-title: Marine sponge natural products with anticancer potential: an updated review
  publication-title: Mar. Drugs
– reference: H. Ren, X. Li, Z. H. Ni, J.Y. Niu, B. Cao, J. Xu, H. Cheng, X. W.Tu, A. M. Ren, Y. Hu, C.Y. Xing, Y.H. Liu, Y.F. Li, J. Cen, R. Zhou, X.D.; Xu, X.H. Qiu, N. Chen, Treatment of complicated urinary tract infection and acute pyelonephritis by short course intravenous levofloxacin (750 mg/day) or conventional intravenous/oral levofloxacin (500mg/day): a prospective, open-label, randomized, controlled, multicenter, non-inferiority clinical trial, Int. Urol. Nephrol. 49 (2017) 499–507.
– volume: 45
  start-page: 8917
  year: 2004
  end-page: 8920
  ident: b0065
  publication-title: Tetrahedron Lett.
– volume: 9
  start-page: 1162
  year: 2018
  ident: b0610
  article-title: Antioxidant and oxidative stress: a mutual interplay in age-related diseases
  publication-title: Front Pharmacol.
– reference: .
– volume: 57
  start-page: 903
  year: 2014
  end-page: 920
  ident: b0975
  article-title: Discovery and optimization of pyrimidone indoline amide pi3kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers
  publication-title: J. Med. Chem.
– volume: 21
  start-page: 1767
  year: 2011
  end-page: 1772
  ident: b1090
  article-title: Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 49
  start-page: 787
  year: 2013
  end-page: 814
  ident: b0070
  article-title: Morpholines synthesis and biological activity
  publication-title: Russ. J. Org. Chem.
– volume: 27
  start-page: 1334
  year: 1999
  end-page: 1340
  ident: b0285
  article-title: Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes
  publication-title: Drug Metab. Dispos.
– volume: 87
  start-page: 38
  year: 2017
  end-page: 53
  ident: b0865
  article-title: The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a γH2AX/p-p53/caspase-3-independent mechanism: Inhibition of calpain and cathepsin D
  publication-title: Int. J. Biochem. Cell Biol.
– volume: 26
  start-page: 1195
  year: 2012
  end-page: 1202
  ident: b1115
  article-title: The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
  publication-title: Leukemia
– volume: 23
  start-page: 479
  year: 2009
  end-page: 484
  ident: b0825
  article-title: Leishmanicidal potential of N-substituted morpholine derivatives: synthesis and structure-activity relationships
  publication-title: Nat. Prod. Res.
– volume: 10
  start-page: 2127
  year: 2012
  end-page: 2136
  ident: b0945
  article-title: Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD 6482 a novel PI3Kβ inhibitor
  publication-title: J. Thromb. Haemost.
– volume: 17
  start-page: 5044
  year: 2015
  end-page: 5047
  ident: b0085
  article-title: Synthesis of 6- and 7-membered
  publication-title: Org. Lett.
– volume: 55
  start-page: 493
  year: 2013
  end-page: 497
  ident: b0510
  article-title: In vivo anti-inflammatory activity and docking study of newly synthesized benzimidazole derivatives bearing oxadiazole and morpholine rings
  publication-title: Food Chem. Toxicol.
– volume: 17
  start-page: 3193
  year: 2011
  end-page: 3203
  ident: b1075
  article-title: Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor
  publication-title: Clin. Cancer Res.
– volume: 334
  start-page: 830
  year: 2010
  end-page: 838
  ident: b1055
  article-title: WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signalling and inhibits the proliferation of transformed cells with oncogenic PI3Kmutant
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 5
  start-page: 479
  year: 2015
  end-page: 483
  ident: b0465
  article-title: Role of aryl urea containing compounds in medicinal chemistry
  publication-title: Med. Chem.
– volume: 154
  start-page: 174
  year: 2018
  end-page: 182
  ident: b0550
  article-title: Novel activities of safe-in-human broad-spectrum antiviral agents
  publication-title: Antiviral Res.
– volume: 73
  start-page: 750
  year: 2017
  end-page: 757
  ident: b0235
  article-title: Synthesis of 3-oxadiazolyl/triazolyl morpholines: novel scaffolds for drug discovery
  publication-title: Tetrahedron
– volume: 7
  start-page: 33
  year: 2006
  ident: b0360
  article-title: Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels
  publication-title: BMC Cell Biol.
– volume: 7
  start-page: 15
  year: 2015
  end-page: 20
  ident: b0375
  article-title: mTOR Inhibitors at a glance
  publication-title: Mol Cell Pharmacol.
– volume: 133
  start-page: 469
  year: 2013
  end-page: 478
  ident: b0520
  article-title: Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function
  publication-title: J. Invest. Dermatol.
– volume: 3
  start-page: 114
  year: 2015
  end-page: 123
  ident: b0640
  article-title: Design and synthesis of some enaminonitrile derivatives of antipyrine as potential novel anti-inflammatory and analgesic agents
  publication-title: J. Biosci. Med.
– volume: 9
  start-page: 976
  year: 2010
  end-page: 984
  ident: b1040
  article-title: Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor
  publication-title: Mol. Cancer Ther.
– volume: 20
  start-page: 5869
  year: 2010
  end-page: 5873
  ident: b1080
  article-title: PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 125
  start-page: 733
  year: 2006
  end-page: 747
  ident: b0930
  article-title: A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling
  publication-title: Cell
– year: 2014, 2014,
  ident: b0615
  article-title: Lipid peroxidation, nitric oxide metabolites, and their ratio in a group of subjects with metabolic syndrome
  publication-title: Oxid. Med. Cell Longev.
– volume: 40
  start-page: 225
  year: 2005
  end-page: 229
  ident: b0735
  article-title: Synthesis of Schiff bases of 4-(4-aminophenyl)-morpholine as potential antimicrobial agents
  publication-title: Eur. J. Med. Chem.
– volume: 14
  start-page: 2508
  year: 2015
  end-page: 2518
  ident: b1130
  article-title: AZD2014, an inhibitor of mtorc1 and mtorc2, is highly effective in breast cancer when administered using intermittent or continuous schedules
  publication-title: Mol. Cancer Ther.
– volume: 6
  start-page: 334
  year: 2018
  ident: b0340
  article-title: A review on anticancer activity of some plant-derived compounds and their mode of action
  publication-title: Nat. Prod. Chem. Res.
– volume: 31
  start-page: 5501
  year: 2003
  end-page: 5512
  ident: b0900
  article-title: Vanillins, novel family of DNA-PK inhibitors
  publication-title: Nucleic Acids Res.
– volume: 124
  start-page: 315
  year: 2018
  end-page: 324
  ident: b0970
  article-title: First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors
  publication-title: Cancer
– volume: 19
  start-page: 5950
  year: 2009
  end-page: 5953
  ident: b1110
  article-title: The discovery and optimisation of Pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR Kinase
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 27
  start-page: 3395
  year: 2017
  end-page: 3398
  ident: b0385
  article-title: Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors
  publication-title: Bioorg. Med. Chem. Lett.
– reference: Z. Shao, Q. Bao, F. Jiang, H. Qian, Q. Fang, X. Hu, VS-5584, a Novel PI3K-mTOR Dual inhibitor, inhibits melanoma cell growth in vitro and in vivo, PLoS One 23 (2015) 10(7):e0132655.
– volume: 21
  start-page: 3532
  year: 2012
  end-page: 3540
  ident: b0525
  article-title: Anti-inflammatory effects of two new methyl and morpholine derivatives of diphenhydramine on rats
  publication-title: Med. Chem. Res.
– volume: 2
  start-page: 774
  year: 2011
  end-page: 779
  ident: b1065
  article-title: Identification of NVP-BKM120 as a Potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer
  publication-title: ACS Med. Chem. Lett.
– volume: 54
  start-page: 7105
  year: 2011
  end-page: 7126
  ident: b0410
  article-title: Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol-3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3, 5-triazin-2-yl]-1
  publication-title: J. Med. Chem.
– volume: 51
  start-page: 1800098
  year: 2018
  ident: b0750
  article-title: The world health organization standards for tuberculosis care and management
  publication-title: Eur. Respir. J.
– volume: 9
  start-page: 50
  year: 2017
  end-page: 56
  ident: b0770
  article-title: Development of new pyrazole hybrids as antitubercular agents: synthesis, biological evaluation and molecular docking study
  publication-title: Int. J. Pharm. Pharm. Sci.
– volume: 23
  start-page: 1212
  year: 2013
  end-page: 1216
  ident: b1120
  article-title: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 132
  start-page: 543
  year: 2018
  end-page: 568
  ident: b1170
  article-title: Drug discovery targeting the mTOR pathway
  publication-title: Clin. Sci. (Lond)
– volume: 4
  start-page: 103
  year: 2013
  end-page: 107
  ident: b1175
  article-title: Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349
  publication-title: ACS Med. Chem. Lett.
– start-page: 523
  year: 1987
  end-page: 542
  ident: b0675
  article-title: The mode of action of dimethylmorpholines
  publication-title: Recent Trends in the Discovery
– volume: 55
  start-page: 493
  year: 2013
  end-page: 497
  ident: b0515
  article-title: Two 6-(propan-2-yl)-4-methyl-morpholine-2,5-diones as new non-purine xanthine oxidase inhibitors and anti-inflammatory agents
  publication-title: Food Chem. Toxicol.
– volume: 64
  start-page: 9152
  year: 2004
  end-page: 9159
  ident: b0875
  article-title: Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM
  publication-title: Cancer Res.
– volume: 35
  start-page: 639
  year: 2012
  end-page: 645
  ident: b0895
  article-title: Improved synthesis of a DNA-dependent protein kinase inhibitor IC86621
  publication-title: Arch. Pharm. Res.
– volume: 80
  start-page: 4349
  year: 2015
  end-page: 4359
  ident: b0095
  article-title: Synthesis of five-, six-, and seven-membered 1,3-and 1,4-heterocyclic compounds via intramolecular hydrothioalkoxylation of alkenols/thioalkenols
  publication-title: J. Org. Chem.
– start-page: 72
  year: 2012
  ident: b0960
  article-title: Identification of GSK2636771, a potent and selective, orally bioavailable inhibitor of phosphatidylinositol 3-kinase-beta (PI3K) for the treatment of PTEN deficient tumors (proceedings of american association for cancer research, 103rd annual meeting, chicago IL, Mar 31−Apr 4, 2012)
  publication-title: Cancer Res.
– volume: 68
  start-page: 7
  year: 2018
  end-page: 30
  ident: b0350
  article-title: Cancer statistics
  publication-title: CA Cancer J. Clin.
– volume: 3
  start-page: 105
  year: 2016
  end-page: 120
  ident: b0620
  article-title: Synthesis, characterization, and antioxidant activities of Novel 1-(Morpholine-4-yl-Methyl) -3-Alkyl(Aryl)-4-[4-(Di methylamino)-Benzylidenamino]-4,5-Dihydro-1H-1,2,4-Triazol-5-Ones
  publication-title: JOTCSA
– reference: S. Patyna, A.D. Laird, D.B. Mendel, A.M. O'farrell, C. Liang, H. Guan, T. Vojkovsky, S. Vasile, X. Wang, J. Chen, M. Grazzini, C.Y. Yang, J.O. Haznedar, J. Sukbuntherng, W.Z. Zhong, J.M. Cherrington, D. Hu-Lowe, SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity, Mol. Cancer Ther. 5 (2006) 1774–1782.
– volume: 22
  start-page: 1211
  year: 2017
  ident: b0420
  article-title: Synthesis, antitumor evaluation and molecular docking of new morpholine based heterocycles
  publication-title: Molecules
– volume: 5
  start-page: 24997
  year: 2015
  end-page: 25005
  ident: b0705
  article-title: Dihydropyrazoles containing morpholine: design, synthesis and bioassay testing as potent antimicrobial agents
  publication-title: RSC Adv.
– volume: 67
  start-page: 5840
  year: 2007
  end-page: 5850
  ident: b0985
  article-title: Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
  publication-title: Cancer Res.
– volume: 269
  start-page: 5241
  year: 1994
  end-page: 5248
  ident: b0835
  article-title: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
  publication-title: J. Biol. Chem.
– reference: E. Vitaku, D.T. Smith, J.T. Njardarson, Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals, J. Med. Chem. 57 (2014) 10257–10274.
– volume: 70
  start-page: 288
  year: 2010
  end-page: 298
  ident: b1125
  article-title: AZD8055 is a potent, selective, and orally bioavailable atp-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity
  publication-title: Cancer Res.
– reference: US Patent 3308121 – 3-Morpholinones, Thiones & 5,6 Oxazines.
– volume: 20
  start-page: 653
  year: 2010
  end-page: 656
  ident: b1035
  article-title: Novel imidazolopyrimidines as dual PI3-kinase/mTOR inhibitors
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 11
  start-page: 1789
  year: 2010
  end-page: 1798
  ident: b0880
  article-title: Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
  publication-title: Mol. Cancer Ther.
– volume: 20
  start-page: 6063
  year: 2012
  end-page: 6072
  ident: b0795
  article-title: Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties
  publication-title: Bioorg. Med. Chem.
– volume: 12
  start-page: 86
  year: 2013
  ident: b0495
  article-title: The complexity of NF-κB signaling in inflammation and cancer
  publication-title: Mol. Cancer
– volume: 70
  start-page: 107
  year: 2017
  end-page: 117
  ident: b0505
  article-title: Selective PCAF inhibitor ameliorates cognitive and behavioral deficits by suppressing NF-κB-mediated neuroinflammation induced by Aβ in a model of Alzheimer's disease
  publication-title: Bioorg. Chem.
– volume: 58
  start-page: 41
  year: 2015
  end-page: 71
  ident: b0405
  article-title: Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKKs) inhibitors: importance of the morpholine ring
  publication-title: J. Med. Chem.
– volume: 256
  start-page: 34
  year: 2000
  end-page: 41
  ident: b0400
  article-title: Serine/threonine protein kinases and apoptosis
  publication-title: Exp. Cell Res.
– volume: 135
  start-page: 479
  year: 2013
  end-page: 491
  ident: b0890
  article-title: Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019
  publication-title: Int. J. Cancer
– volume: 50
  start-page: 27
  year: 2009
  end-page: 34
  ident: b0060
  article-title: Characterization of metabolic profile of mosapride citrate in rat and identification of two new metabolites: mosapride N-oxide and morpholine ring-opened mosapride by UPLC-ESI-MS/MS
  publication-title: J. Pharm. Biomed. Anal.
– volume: 2018
  start-page: 9872095
  year: 2018
  ident: b0805
  article-title: Current visceral leishmaniasis research: a research review to inspire future study
  publication-title: Biomed. Res. Int.
– volume: 22
  start-page: 6746
  year: 2014
  end-page: 6754
  ident: b0460
  article-title: Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihyd ro-5H-thiopyrano[4,3-d] pyrimidine derivatives as mTOR inhibitors
  publication-title: Bioorg. Med. Chem.
– volume: 8
  start-page: 2894
  year: 2009
  end-page: 2902
  ident: b0885
  article-title: Improved ATM kinase inhibitor ku-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
  publication-title: Mol. Cancer Ther.
– volume: 129
  start-page: 57
  year: 2016
  end-page: 66
  ident: b1060
  article-title: Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
  publication-title: J. Neurooncol.
– volume: 24
  start-page: 630
  year: 2019
  ident: b0230
  article-title: Stereoselective multicomponent reactions in the synthesis or transformations of epoxides and aziridines
  publication-title: Molecules
– volume: 102
  start-page: 606
  year: 1986
  end-page: 611
  ident: b0145
  article-title: Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985
  publication-title: Amer. J. Ophthalmol.
– volume: 58
  start-page: 258
  year: 2014
  end-page: 266
  ident: b0190
  article-title: Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factor
  publication-title: Antimicrob. Agents Chemother.
– volume: 345
  start-page: 784
  year: 1993
  end-page: 786
  ident: b0035
  article-title: Simultaneous determination of fenpropimorph and the corresponding metabolite fenpropimorphic acid in soil
  publication-title: Fresenius J. Anal. Chem.
– volume: 2
  start-page: 1257
  year: 2003
  end-page: 1264
  ident: b0915
  article-title: DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer
  publication-title: Mol. Cancer Ther.
– volume: 9
  start-page: 976
  year: 2010
  end-page: 984
  ident: b1030
  article-title: Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus Mtor
  publication-title: Mol. Cancer Ther.
– volume: 12
  start-page: 25
  year: 2017
  end-page: 40
  ident: b0810
  article-title: Leishmaniasis in humans: drug or vaccine therapy?
  publication-title: Drug Des. Devel. Ther.
– volume: 89
  year: 2019
  ident: b0010
  article-title: Medicinal chemistry of indole derivatives: current to future therapeutic prospective
  publication-title: Bioorg. Chem.
– volume: 20
  start-page: 5908
  year: 2014
  end-page: 5917
  ident: b1085
  article-title: The first-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
  publication-title: Clin. Cancer Res.
– volume: 38
  start-page: 2836
  year: 2017
  end-page: 2842
  ident: b0935
  article-title: TGX-221 inhibits proliferation and induces apoptosis in human glioblastoma cells
  publication-title: Oncol. Rep.
– volume: 2014
  year: 2014
  ident: b1105
  article-title: Differential role of rapamycin and Torin/KU63794 in inflammatory response of 264.7 RAW macrophages stimulated by CA-MRSA
  publication-title: Int. J. Inflam.
– volume: 41
  start-page: 5
  year: 1995
  ident: b0120
  publication-title: Heterocycles
– volume: 32
  year: 2014
  ident: b0965
  article-title: Phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors
  publication-title: J. Clin. Oncol.
– volume: 35
  start-page: 1135
  year: 2007
  end-page: 1141
  ident: b0305
  article-title: Timolol metabolism in human liver microsomes is mediated principally by CYP2D6
  publication-title: Drug Metab. Dispos.
– volume: 167
  start-page: 324
  year: 2019
  end-page: 356
  ident: b0250
  article-title: Revealing quinquennial anticancer journey of morpholine: a SAR based review
  publication-title: Eur. J. Med. Chem.
– volume: 47
  start-page: 4512
  year: 2008
  ident: b0320
  article-title: Spirocyclic oxetanes: synthesis and properties
  publication-title: Angew. Chem. Int. Ed.
– volume: 6
  start-page: 60
  year: 2010
  end-page: 65
  ident: b0715
  article-title: Evaluation of benzophenone-N-ethyl morpholine ethers as antibacterial and antifungal activities
  publication-title: J. Chem. Int. J. Biomed. Sci.
– reference: file:///C:/Users/PEARL/Downloads/Asymmetric+Synthesis+of+2%252C2%E2%80%99-Bimorpholine+and+its+5%252C5%E2%80%99-Substituted+Derivatives%20(1).pdf.
– volume: 120
  start-page: 296
  year: 2016
  end-page: 303
  ident: b0430
  article-title: Synthesis and biological screening for cytotoxic activity of
  publication-title: Eur. J. Med. Chem.
– volume: 40
  start-page: 1377
  year: 2005
  end-page: 1383
  ident: b0485
  article-title: Pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors. Synthesis and SAR of 2-substituted 4-methyl-8-(morpholine-4-sulfonyl)-pyrrolo[3,4-c]quinoline-1,3-diones
  publication-title: Eur. J. Med. Chem.
– volume: 19
  start-page: 5679
  year: 2011
  end-page: 5692
  ident: b0040
  article-title: Synthesis and glycosidase inhibitory profiles of functionalized morpholines and oxazepanes
  publication-title: Bioorg. Med. Chem.
– volume: 27
  start-page: 66
  year: 2017
  end-page: 71
  ident: b0425
  article-title: Synthesis of new morpholine-connected pyrazolidine derivatives and their antimicrobial, antioxidant, and cytotoxic activities
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 12
  start-page: 4749
  year: 2004
  end-page: 4759
  ident: b0925
  article-title: Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold
  publication-title: Bioorg. Med. Chem.
– volume: 14
  start-page: 1234
  year: 2012
  end-page: 1237
  ident: b0105
  article-title: Intramolecular Pd(II) catalyzed aerobic oxidative amination of alkenes: synthesis of six-membered N-heterocycles
  publication-title: Org. Lett.
– volume: 32
  start-page: 1287
  year: 2004
  end-page: 1292
  ident: b0280
  article-title: Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant
  publication-title: Drug Metab. Dispos.
– volume: 4
  start-page: 353
  year: 2017
  end-page: 364
  ident: b0555
  article-title: Synthesis and antiviral activity of 4-(7,7-dimethyl-4-[4-{N-aroyl/benzyl}1- piperazinyl]-5,6,7,8-tetra hydro quinazolin-2-yl)morpholine derivatives
  publication-title: Arkivoc
– volume: 5
  start-page: 544
  year: 2014
  end-page: 549
  ident: b0245
  article-title: Development of novel benzo morpholine class of diacylglycerol acyltransferase I inhibitors
  publication-title: Med. Chem. Lett.
– volume: 59
  start-page: 1868
  year: 2015
  end-page: 1875
  ident: b0780
  article-title: Gyrase inhibitors as a new class of antitubercular drugs
  publication-title: Antimicrob. Agents Chemother.
– volume: 98
  start-page: 227
  year: 2011
  end-page: 233
  ident: b0645
  article-title: New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats
  publication-title: Pharmacol. Biochem. Behav.
– volume: 14
  start-page: 1777
  year: 2016
  end-page: 1788
  ident: b0015
  article-title: Emphasizing morpholine and its derivatives (MAID): typical candidate of pharmaceutical importance
  publication-title: Int. J. Chem. Sci.
– reference: R. Surendra Kumar, M. Moydeen, S.S. Al-Deyab, A. Manilal, A. Idhayadhulla, Synthesis of new morpholine-connected pyrazolidine derivatives and their antimicrobial, antioxidant, and cytotoxic activities, Bioorg. Med. Chem. Lett. 27 (2017) 66–71.
– volume: 2004
  start-page: 641
  year: 2004
  end-page: 662
  ident: b0225
  article-title: Biological relevance and synthesis of C-substituted morpholine derivatives
  publication-title: Synthesis
– reference: (accessed on 02 April 2019).
– volume: 2
  start-page: 5
  year: 2010
  end-page: 12
  ident: b0730
  article-title: Synthesis of novel piperazine and morpholine linked substituted pyrimidine derivatives as antimicrobial agents
  publication-title: J. Pharm. Sci. Res.
– volume: 20
  start-page: 2644
  year: 2010
  end-page: 2647
  ident: b0390
  article-title: Discovery of 2-ureido phenyl triazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 56
  start-page: 1315
  year: 2012
  end-page: 1323
  ident: b0565
  article-title: Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication
  publication-title: Antimicrob. Agents Chemother.
– start-page: 2939
  year: 2011
  end-page: 2942
  ident: b0045
  article-title: Synthesis of a chiral key intermediate of neurokinin antagonist SSR 240600 by asymmetric allylic alkylation
  publication-title: Synlett
– reference: US patent 2943022, H. Siemer, A. Doppstadt, Substituted 1-phenyl-2,3-dimethyl-4-morpholino methyl pyrazolone-(5) compounds and process of making same, issued 1960-06-28, assigned to Ravensberg.
– volume: 1016
  start-page: 147
  year: 2012
  end-page: 154
  ident: b0725
  article-title: Synthesis, structure and antimicrobial activity of 6-(propan-2-yl)-3-methyl-morpholine-2, 5-dione
  publication-title: J. Mol. Struct.
– volume: 50
  start-page: 1958
  year: 2007
  end-page: 1972
  ident: b0870
  article-title: Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase
  publication-title: J. Med. Chem.
– volume: 12
  start-page: 151
  year: 2013
  end-page: 161
  ident: b1100
  article-title: VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer
  publication-title: Mol. Cancer Ther.
– volume: 17
  start-page: 127
  year: 2017
  ident: b0630
  article-title: Analgesic-antipyretic use among young children in the TEDDY study: no association with islet autoimmunity
  publication-title: BMC Pediatr.
– volume: 7
  start-page: 702
  year: 2016
  end-page: 707
  ident: b0560
  article-title: Discovery of MK-8718, an HIV protease inhibitor containing a novel morpholine aspartate binding group
  publication-title: ACS Med. Chem. Lett.
– volume: 140
  start-page: 92
  year: 2017
  end-page: 103
  ident: b0500
  article-title: TNF-α and IL-6 inhibitors: conjugates of N-substituted indole and aminophenylmorpholin-3-one as anti-inflammatory agents
  publication-title: Eur. J. Med. Chem.
– volume: 18
  start-page: 1199
  year: 2018
  end-page: 1219
  ident: b0635
  article-title: Prodrugs of non-steroidal anti-inflammatory drugs (NSAIDs): a long march towards synthesis of safer NSAIDs
  publication-title: Mini Rev. Med. Chem.
– volume: 4
  start-page: 778
  year: 2014
  end-page: 783
  ident: b0710
  article-title: Synthesis, antimicrobial and antioxidant activities of novel series of cinnamamide derivatives having morpholine moiety
  publication-title: Med. Chem.
– volume: 3
  start-page: 462
  year: 2012
  end-page: 469
  ident: b0800
  article-title: Design and synthesis of novel N-substituted morpholino benzamide derivatives as antimicrobial agents
  publication-title: Der. Pharmacia. Sinica
– volume: 14
  start-page: 2449
  year: 2014
  end-page: 2467
  ident: b0020
  article-title: Perspectives on 1, 4-benzo dioxions,1, 4-benzoxazines and their 2, 3- dihydro derivatives
  publication-title: Synlett
– volume: 23
  start-page: 7015
  year: 2015
  end-page: 7023
  ident: b0600
  article-title: Antihyperlipidemic morpholine derivatives with antioxidant activity: an investigation of the aromatic substitution
  publication-title: Bioorg. Med. Chem.
– volume: 50
  start-page: 606
  year: 2017
  end-page: 612
  ident: b0830
  article-title: PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells
  publication-title: Int. J. Oncol.
– volume: 76
  start-page: 2594
  year: 2011
  end-page: 2602
  ident: b0050
  article-title: Asymmetric synthesis of an antagonist of neurokinin receptors: SSR 241586
  publication-title: J. Org. Chem.
– reference: M.T. Burger, S. Pecchi, A. Wagman, Z.-J. Ni, M. Knapp, T. Hendrickson, G. Atallah, K. Pfister, Y.C. Zhang, S. Bartulis, K. Frazier, S. Ng, A. Smith, J. Verhagen, J. Haznedar, K. Huh, E. Iwanowicz, X.H. Xin, D. Menezes, H. Merritt, I. Lee, M. Wiesmann, S. Kaufman, K. Crawford, M. Chin, D. Bussiere, K. Shoemaker, I. Zaror, S.-M. Maira, C.F. Voliva, Identification of NVP-BKM120 as a potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer, ACS Med. Chem. Lett. 2 (2011) 774e779.
– volume: 45
  start-page: 7736
  year: 2006
  ident: b0310
  article-title: Oxetanes as promising modules in drug discovery
  publication-title: Angew. Chem. Int. Ed.
– volume: 52
  start-page: 5013
  year: 2009
  end-page: 5016
  ident: b1155
  article-title: ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines
  publication-title: J. Med. Chem.
– volume: 52
  start-page: 8010
  year: 2009
  end-page: 8024
  ident: b1140
  article-title: Discovery of 4-Morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent
  publication-title: J. Med. Chem.
– volume: 99
  start-page: 1
  year: 2015
  end-page: 13
  ident: b0455
  article-title: Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors
  publication-title: Eur. J. Med. Chem.
– volume: 22
  start-page: 613
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0450
  article-title: Synthesis of pyrrolo[1,2-a]pyrimidine enantiomers via domino ring-closure followed by retrodiels-alder protocol
  publication-title: Molecules
  doi: 10.3390/molecules22040613
– volume: 68
  start-page: 7
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0350
  article-title: Cancer statistics
  publication-title: CA Cancer J. Clin.
– volume: 52
  start-page: 5013
  year: 2009
  ident: 10.1016/j.bioorg.2020.103578_b1155
  article-title: ATP-competitive inhibitors of the mammalian target of rapamycin: design and synthesis of highly potent and selective pyrazolopyrimidines
  publication-title: J. Med. Chem.
  doi: 10.1021/jm900851f
– volume: 57
  start-page: 2568
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0595
  article-title: Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity
  publication-title: J. Med. Chem.
  doi: 10.1021/jm401842e
– volume: 87
  start-page: 171
  year: 1996
  ident: 10.1016/j.bioorg.2020.103578_b0475
  article-title: Human ICE/CED-3 protease nomenclature
  publication-title: Cell
  doi: 10.1016/S0092-8674(00)81334-3
– volume: 379
  start-page: 1672
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0740
  article-title: New promise for vaccines against tuberculosis
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMe1812483
– volume: 12
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b1150
  article-title: Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo
  publication-title: PLoS ONE
– volume: 34
  start-page: 1660
  issue: 14
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b1010
  article-title: Randomized open-label phase II trial of Apitolisib (GDC-0980), a novel inhibitor of the PI3k/mammalian target of rapamycin pathway, versus everolimus in patients with metastatic renal cell carcinoma
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.64.8808
– ident: 10.1016/j.bioorg.2020.103578_b0545
– volume: 23
  start-page: 479
  year: 2009
  ident: 10.1016/j.bioorg.2020.103578_b0825
  article-title: Leishmanicidal potential of N-substituted morpholine derivatives: synthesis and structure-activity relationships
  publication-title: Nat. Prod. Res.
  doi: 10.1080/14786410802090359
– volume: 45
  start-page: 8917
  year: 2004
  ident: 10.1016/j.bioorg.2020.103578_b0065
  publication-title: Tetrahedron Lett.
  doi: 10.1016/j.tetlet.2004.09.185
– volume: 18
  start-page: 1199
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0635
  article-title: Prodrugs of non-steroidal anti-inflammatory drugs (NSAIDs): a long march towards synthesis of safer NSAIDs
  publication-title: Mini Rev. Med. Chem.
  doi: 10.2174/1389557518666180330112416
– volume: 29
  start-page: 1136
  year: 2009
  ident: 10.1016/j.bioorg.2020.103578_b0265
  article-title: “Pharmacokinetics metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects
  publication-title: Drug Metab. Dispos.
– volume: 44
  start-page: 343
  year: 1998
  ident: 10.1016/j.bioorg.2020.103578_b0200
  article-title: Clinical pharmacology of systemic antifungal agents: a comprehensive review of agents in clinical use, current investigational compounds and putative targets for antifungal drug development
  publication-title: Adv. Pharmacol.
  doi: 10.1016/S1054-3589(08)60129-5
– volume: 15
  start-page: 310
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0130
  article-title: Marine sponge natural products with anticancer potential: an updated review
  publication-title: Mar. Drugs
  doi: 10.3390/md15100310
– volume: 69
  start-page: 3796
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b0325
  article-title: Synthesis of 2- and 3-trifluoromethylmorpholines: useful building blocks for drug discovery
  publication-title: Tetrahedron
  doi: 10.1016/j.tet.2013.03.067
– volume: 76
  start-page: 2594
  year: 2011
  ident: 10.1016/j.bioorg.2020.103578_b0050
  article-title: Asymmetric synthesis of an antagonist of neurokinin receptors: SSR 241586
  publication-title: J. Org. Chem.
  doi: 10.1021/jo102471r
– volume: 98
  start-page: 227
  year: 2011
  ident: 10.1016/j.bioorg.2020.103578_b0645
  article-title: New morpholine analogues of phencyclidine: chemical synthesis and pain perception in rats
  publication-title: Pharmacol. Biochem. Behav.
  doi: 10.1016/j.pbb.2010.12.019
– volume: 69
  start-page: 6232
  year: 2009
  ident: 10.1016/j.bioorg.2020.103578_b1145
  article-title: Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of Rapamycin
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-09-0299
– volume: 19
  start-page: 5950
  year: 2009
  ident: 10.1016/j.bioorg.2020.103578_b1110
  article-title: The discovery and optimisation of Pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR Kinase
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2009.08.038
– ident: 10.1016/j.bioorg.2020.103578_b0170
  doi: 10.1016/j.pbb.2010.07.020
– volume: 21
  start-page: 3532
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0525
  article-title: Anti-inflammatory effects of two new methyl and morpholine derivatives of diphenhydramine on rats
  publication-title: Med. Chem. Res.
  doi: 10.1007/s00044-011-9891-y
– volume: 2
  start-page: 721
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0100
  article-title: Synthesis of morpholine or piperazine derivatives through gold-catalyzed cyclization reactions of alkynylamines or alkynylalcohols
  publication-title: Org. Chem. Front.
  doi: 10.1039/C5QO00060B
– ident: 10.1016/j.bioorg.2020.103578_b0355
  doi: 10.1158/1535-7163.MCT-05-0333
– volume: 50
  start-page: 1958
  year: 2007
  ident: 10.1016/j.bioorg.2020.103578_b0870
  publication-title: J. Med. Chem.
  doi: 10.1021/jm061121y
– volume: 9
  start-page: 146
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0685
  article-title: Synthesis and evaluation of the biological activity of new 4-(2-chloroacetyl) morpholine
  publication-title: J. Chem. Pharm. Res.
– volume: 31
  start-page: 8
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b1135
  article-title: Current development of the second generation of mTOR inhibitors as anticancer agents
  publication-title: Chin. J. Cancer
– volume: 4
  start-page: 351
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0790
  article-title: Novel Mannich bases of 4-thiazolidinon derivatives as antitubercular agents
  publication-title: IJRPC
– volume: 87
  start-page: 38
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0865
  article-title: The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a γH2AX/p-p53/caspase-3-independent mechanism: Inhibition of calpain and cathepsin D
  publication-title: Int. J. Biochem. Cell Biol.
  doi: 10.1016/j.biocel.2017.03.015
– volume: 11
  start-page: 1789
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b0880
  article-title: Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-11-0535
– volume: 7
  start-page: 15
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0375
  article-title: mTOR Inhibitors at a glance
  publication-title: Mol Cell Pharmacol.
– volume: 49
  start-page: 787
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b0070
  article-title: Morpholines synthesis and biological activity
  publication-title: Russ. J. Org. Chem.
  doi: 10.1134/S1070428013060018
– volume: 53
  start-page: 343
  issue: 3
  year: 2019
  ident: 10.1016/j.bioorg.2020.103578_b0540
  article-title: Recent advances in the vaccines development for the treatment of emerging infectious diseases
  publication-title: Ind. J. Pharm. Edu. Res.
  doi: 10.5530/ijper.53.3.68
– volume: 11
  start-page: 524
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0090
  article-title: Metal-free one-pot synthesis of 2-substituted and 2,3-disubstituted morpholines from aziridines
  publication-title: Beilstein J. Org. Chem.
  doi: 10.3762/bjoc.11.59
– volume: 20
  start-page: 2408
  issue: 8
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b1000
  article-title: Identification of GNE-477, a potent and efficacious dual PI3K/mTOR inhibitor
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2010.03.046
– volume: 17
  start-page: 1
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0665
  article-title: Linezolid update: stable in vitro activity following more than a decade of clinical use and summary of associated resistance mechanisms
  publication-title: Drug Resist. Updat.
  doi: 10.1016/j.drup.2014.04.002
– volume: 50
  start-page: 27
  year: 2009
  ident: 10.1016/j.bioorg.2020.103578_b0060
  article-title: Characterization of metabolic profile of mosapride citrate in rat and identification of two new metabolites: mosapride N-oxide and morpholine ring-opened mosapride by UPLC-ESI-MS/MS
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2009.03.011
– volume: 20
  start-page: 450
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0140
  article-title: Aprepitant and fosaprepitant: a 10-year review of efficacy and safety
  publication-title: Oncologist
  doi: 10.1634/theoncologist.2014-0229
– volume: 20
  start-page: 5869
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b1080
  article-title: PKI-179: an orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2010.07.104
– volume: 345
  start-page: 784
  year: 1993
  ident: 10.1016/j.bioorg.2020.103578_b0035
  article-title: Simultaneous determination of fenpropimorph and the corresponding metabolite fenpropimorphic acid in soil
  publication-title: Fresenius J. Anal. Chem.
  doi: 10.1007/BF00323011
– ident: 10.1016/j.bioorg.2020.103578_b0690
  doi: 10.1016/j.bmcl.2016.11.032
– volume: 68
  start-page: 951
  year: 2005
  ident: 10.1016/j.bioorg.2020.103578_b0125
  article-title: Hectochlorin and morpholine derivatives from the Thai sea hare, Bursatella leachii
  publication-title: J. Nat. Prod.
  doi: 10.1021/np0500124
– volume: 35
  start-page: 649
  year: 1993
  ident: 10.1016/j.bioorg.2020.103578_b0300
  article-title: Moclobemide treatment causes a substantial rise in the sparteine metabolic ratio. Danish University Antidepressant Group
  publication-title: Br. J. Clin. Pharmacol.
  doi: 10.1111/j.1365-2125.1993.tb04196.x
– volume: 6
  start-page: 334
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0340
  article-title: A review on anticancer activity of some plant-derived compounds and their mode of action
  publication-title: Nat. Prod. Chem. Res.
– volume: 24
  start-page: 630
  year: 2019
  ident: 10.1016/j.bioorg.2020.103578_b0230
  article-title: Stereoselective multicomponent reactions in the synthesis or transformations of epoxides and aziridines
  publication-title: Molecules
  doi: 10.3390/molecules24030630
– volume: 73
  start-page: 750
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0235
  article-title: Synthesis of 3-oxadiazolyl/triazolyl morpholines: novel scaffolds for drug discovery
  publication-title: Tetrahedron
  doi: 10.1016/j.tet.2016.12.052
– volume: 2
  start-page: 5
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b0730
  article-title: Synthesis of novel piperazine and morpholine linked substituted pyrimidine derivatives as antimicrobial agents
  publication-title: J. Pharm. Sci. Res.
– volume: 341
  start-page: 4737
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b0165
  article-title: Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials
  publication-title: BMJ
  doi: 10.1136/bmj.c4737
– volume: 52
  start-page: 8010
  year: 2009
  ident: 10.1016/j.bioorg.2020.103578_b1140
  article-title: Discovery of 4-Morpholino-6-aryl-1H-pyrazolo[3,4-d]pyrimidines as highly potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): optimization of the 6-aryl substituent
  publication-title: J. Med. Chem.
  doi: 10.1021/jm9013828
– ident: 10.1016/j.bioorg.2020.103578_b0150
– volume: 14
  start-page: 1777
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0015
  article-title: Emphasizing morpholine and its derivatives (MAID): typical candidate of pharmaceutical importance
  publication-title: Int. J. Chem. Sci.
– volume: 23
  start-page: 7015
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0600
  article-title: Antihyperlipidemic morpholine derivatives with antioxidant activity: an investigation of the aromatic substitution
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2015.09.034
– volume: 3
  start-page: 373
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0470
  article-title: URD12: a urea derivative with marked antitumor activities
  publication-title: Oncol. Lett.
  doi: 10.3892/ol.2011.474
– ident: 10.1016/j.bioorg.2020.103578_b0195
– volume: 85
  start-page: 182
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0575
  article-title: Therapeutic role of nitric oxide as emerging molecules
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2016.11.125
– volume: 12
  start-page: 4749
  year: 2004
  ident: 10.1016/j.bioorg.2020.103578_b0925
  article-title: Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2004.06.022
– volume: 40
  start-page: 225
  year: 2005
  ident: 10.1016/j.bioorg.2020.103578_b0735
  article-title: Synthesis of Schiff bases of 4-(4-aminophenyl)-morpholine as potential antimicrobial agents
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2004.09.003
– start-page: 523
  year: 1987
  ident: 10.1016/j.bioorg.2020.103578_b0675
  article-title: The mode of action of dimethylmorpholines
– ident: 10.1016/j.bioorg.2020.103578_b0025
– volume: 20
  start-page: 6063
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0795
  article-title: Antitubercular nitrofuran isoxazolines with improved pharmacokinetic properties
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2012.08.023
– volume: 45
  start-page: 7736
  year: 2006
  ident: 10.1016/j.bioorg.2020.103578_b0310
  article-title: Oxetanes as promising modules in drug discovery
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.200602343
– volume: 89
  year: 2019
  ident: 10.1016/j.bioorg.2020.103578_b0010
  article-title: Medicinal chemistry of indole derivatives: current to future therapeutic prospective
  publication-title: Bioorg. Chem.
  doi: 10.1016/j.bioorg.2019.103021
– volume: 7
  start-page: 33
  year: 2006
  ident: 10.1016/j.bioorg.2020.103578_b0360
  article-title: Glycogen synthase kinase 3 has a limited role in cell cycle regulation of cyclin D1 levels
  publication-title: BMC Cell Biol.
  doi: 10.1186/1471-2121-7-33
– volume: 7
  start-page: 65
  year: 1982
  ident: 10.1016/j.bioorg.2020.103578_b0290
  article-title: Pharmacokinetics of viloxazine hydrochloride in man
  publication-title: Eur. J. Drug Metab. Pharmacokinet.
  doi: 10.1007/BF03189545
– volume: 5
  start-page: 479
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0465
  article-title: Role of aryl urea containing compounds in medicinal chemistry
  publication-title: Med. Chem.
– volume: 14
  start-page: 2449
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0020
  article-title: Perspectives on 1, 4-benzo dioxions,1, 4-benzoxazines and their 2, 3- dihydro derivatives
  publication-title: Synlett
– ident: 10.1016/j.bioorg.2020.103578_b0570
– volume: 27
  start-page: 3395
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0385
  article-title: Design, synthesis and biological evaluation of novel 3H-imidazole [4,5-b] pyridine derivatives as selective mTOR inhibitors
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2017.06.010
– volume: 40
  start-page: 1377
  year: 2005
  ident: 10.1016/j.bioorg.2020.103578_b0485
  article-title: Pyrrolo[3,4-c]quinoline-1,3-diones as potent caspase-3 inhibitors. Synthesis and SAR of 2-substituted 4-methyl-8-(morpholine-4-sulfonyl)-pyrrolo[3,4-c]quinoline-1,3-diones
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2005.07.011
– volume: 51
  start-page: 5522
  year: 2008
  ident: 10.1016/j.bioorg.2020.103578_b0995
  article-title: The identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
  publication-title: J. Med. Chem.
  doi: 10.1021/jm800295d
– volume: 35
  start-page: 1109
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0490
  article-title: Inflammation: the common pathway of stress-related diseases
  publication-title: Int. J. Mol. Med.
– volume: 12
  start-page: 86
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b0495
  article-title: The complexity of NF-κB signaling in inflammation and cancer
  publication-title: Mol. Cancer
  doi: 10.1186/1476-4598-12-86
– volume: 544
  start-page: 221
  year: 1988
  ident: 10.1016/j.bioorg.2020.103578_b0670
  article-title: Mode of action of morpholine derivatives
  publication-title: Ann. N. Y. Acad. Sci.
  doi: 10.1111/j.1749-6632.1988.tb40406.x
– volume: 9
  start-page: 976
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b1030
  article-title: Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus Mtor
  publication-title: Mol. Cancer Ther.
– volume: 6
  start-page: 117
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b1050
  article-title: The p110 delta structure: mechanisms for selectivity and potency of new PI(3)K inhibitors
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/nchembio.293
– ident: 10.1016/j.bioorg.2020.103578_b0445
  doi: 10.1021/ml200156t
– volume: 22
  start-page: 5268
  issue: 18
  year: 2006
  ident: 10.1016/j.bioorg.2020.103578_b0365
  article-title: The epidermal growth factor receptor pathway: a model for targeted therapy
  publication-title: Clin Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-1554
– volume: 17
  start-page: 127
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0630
  article-title: Analgesic-antipyretic use among young children in the TEDDY study: no association with islet autoimmunity
  publication-title: BMC Pediatr.
  doi: 10.1186/s12887-017-0884-y
– volume: 32
  start-page: 1287
  year: 2004
  ident: 10.1016/j.bioorg.2020.103578_b0280
  article-title: Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.104.000216
– volume: 7
  start-page: 702
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0560
  article-title: Discovery of MK-8718, an HIV protease inhibitor containing a novel morpholine aspartate binding group
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/acsmedchemlett.6b00135
– volume: 7
  start-page: 281
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0135
  article-title: Piperazine and morpholine: synthetic preview and pharmaceutical applications
  publication-title: J. Chem. Pharm. Res.
– volume: 4
  start-page: 353
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0555
  article-title: Synthesis and antiviral activity of 4-(7,7-dimethyl-4-[4-{N-aroyl/benzyl}1- piperazinyl]-5,6,7,8-tetra hydro quinazolin-2-yl)morpholine derivatives
  publication-title: Arkivoc
  doi: 10.24820/ark.5550190.p010.037
– ident: 10.1016/j.bioorg.2020.103578_b0180
– volume: 334
  start-page: 830
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b1055
  article-title: WJD008, a dual phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin inhibitor, prevents PI3K signalling and inhibits the proliferation of transformed cells with oncogenic PI3Kmutant
  publication-title: J. Pharmacol. Exp. Ther.
  doi: 10.1124/jpet.110.167940
– ident: 10.1016/j.bioorg.2020.103578_b0175
  doi: 10.1007/978-94-011-3804-8
– volume: 55
  start-page: 493
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b0510
  article-title: In vivo anti-inflammatory activity and docking study of newly synthesized benzimidazole derivatives bearing oxadiazole and morpholine rings
  publication-title: Food Chem. Toxicol.
– volume: 133
  start-page: 469
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b0520
  article-title: Topical antihistamines display potent anti-inflammatory activity linked in part to enhanced permeability barrier function
  publication-title: J. Invest. Dermatol.
  doi: 10.1038/jid.2012.335
– volume: 23
  start-page: 34
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0695
  article-title: Modulation of the antibiotic activity against multidrug resistant strains of 4-(phenylsulfonyl) morpholine
  publication-title: Saudi.J Biol. Sci.
  doi: 10.1016/j.sjbs.2015.02.001
– volume: 22
  start-page: 1374
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0700
  article-title: Pharmacological and toxicological screening of novel benzimidazole-morpholine derivatives as dual-acting inhibitors
  publication-title: Molecules
  doi: 10.3390/molecules22081374
– volume: 76
  start-page: 10325
  year: 2011
  ident: 10.1016/j.bioorg.2020.103578_b0030
  article-title: Stereoselective synthesis of C-substituted morpholine derivatives using reductive etherification reaction: total synthesis of chelonin C
  publication-title: J. Org. Chem.
  doi: 10.1021/jo201975b
– volume: 47
  start-page: 7823
  year: 2006
  ident: 10.1016/j.bioorg.2020.103578_b0240
  article-title: Synthesis of substituted 4-(3-alkyl-1, 2, 4-oxadiazol-5-yl methyl)-3,4-dihydro-2H-1,4-benzoxazines and-4-(1H-benzimidazol-2-ylmethyl)-3,4-dihydro-2H 1,4 benzoxazines
  publication-title: Tetrahedron Lett.
  doi: 10.1016/j.tetlet.2006.08.029
– volume: 3
  start-page: 105
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0620
  article-title: Synthesis, characterization, and antioxidant activities of Novel 1-(Morpholine-4-yl-Methyl) -3-Alkyl(Aryl)-4-[4-(Di methylamino)-Benzylidenamino]-4,5-Dihydro-1H-1,2,4-Triazol-5-Ones
  publication-title: JOTCSA
  doi: 10.18596/jotcsa.23635
– volume: 56
  start-page: 1315
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0565
  article-title: Identification of novel N-(morpholine-4-carbonyloxy) amidine compounds as potent inhibitors against hepatitis C virus replication
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.05764-11
– volume: 269
  start-page: 5241
  year: 1994
  ident: 10.1016/j.bioorg.2020.103578_b0835
  article-title: A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
  publication-title: J. Biol. Chem.
  doi: 10.1016/S0021-9258(17)37680-9
– volume: 22
  start-page: 5208
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b1025
  article-title: Rapid Identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2012.06.093
– volume: 58
  start-page: 41
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0405
  article-title: Phosphatidylinositol 3-Kinase (PI3K) and phosphatidylinositol 3-kinase-related kinase (PIKKs) inhibitors: importance of the morpholine ring
  publication-title: J. Med. Chem.
  doi: 10.1021/jm501026z
– volume: 124
  start-page: 315
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0970
  article-title: First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors
  publication-title: Cancer
  doi: 10.1002/cncr.31044
– volume: 61
  start-page: 8934
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0335
  article-title: Lowering lipophilicity by adding carbon: one-carbon bridges of morpholines and piperazines
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01148
– volume: 21
  start-page: 1767
  year: 2011
  ident: 10.1016/j.bioorg.2020.103578_b1090
  article-title: Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2011.01.065
– volume: 10
  start-page: 98
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0605
  article-title: Optimizing the pharmacological profile of new bifunctional antihyperlipidemic/antioxidant morpholine derivatives
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/acsmedchemlett.8b00469
– volume: 1016
  start-page: 147
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0725
  article-title: Synthesis, structure and antimicrobial activity of 6-(propan-2-yl)-3-methyl-morpholine-2, 5-dione
  publication-title: J. Mol. Struct.
  doi: 10.1016/j.molstruc.2012.02.057
– volume: 38
  start-page: 2836
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0935
  article-title: TGX-221 inhibits proliferation and induces apoptosis in human glioblastoma cells
  publication-title: Oncol. Rep.
  doi: 10.3892/or.2017.5991
– volume: 4
  start-page: 207
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0840
  article-title: SF1126, a Pan-PI3K inhibitor has potent pre-clinical activity in aggressive B-cell non-Hodgkin lymphomas by inducing cell cycle arrest and apoptosis
  publication-title: J. Cancer Sci. Ther.
– volume: 9
  issue: 5
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b1180
  article-title: Targeting the ATR-CHK1 axis in cancer therapy
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers9050041
– volume: 29
  start-page: 1443
  year: 2008
  ident: 10.1016/j.bioorg.2020.103578_b0110
  article-title: Preparation of morpholine-2-one and 1,4-oxazepan-2-one derivatives by cyclization reaction between N-Bts amino alcohol and chloroacetyl chloride
  publication-title: Bull. Korean Chem. Soc.
  doi: 10.5012/bkcs.2008.29.8.1443
– volume: 99
  start-page: 1
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0455
  article-title: Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2015.05.036
– volume: 7
  start-page: 38191
  issue: 25
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0980
  article-title: Dual PI3K- and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: the role of drug-irradiation schedule
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.9501
– volume: 154
  start-page: 174
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0550
  article-title: Novel activities of safe-in-human broad-spectrum antiviral agents
  publication-title: Antiviral Res.
  doi: 10.1016/j.antiviral.2018.04.016
– year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0615
  article-title: Lipid peroxidation, nitric oxide metabolites, and their ratio in a group of subjects with metabolic syndrome
  publication-title: Oxid. Med. Cell Longev.
  doi: 10.1155/2014/824756
– volume: 125
  start-page: 733
  year: 2006
  ident: 10.1016/j.bioorg.2020.103578_b0930
  article-title: A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling
  publication-title: Cell
  doi: 10.1016/j.cell.2006.03.035
– volume: 1
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0920
  article-title: Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment
  publication-title: Mol. Cell Oncol.
– volume: 120
  start-page: 296
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0430
  article-title: Synthesis and biological screening for cytotoxic activity of N-substituted indolines and morpholines
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2016.05.024
– volume: 70
  start-page: 107
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0505
  article-title: Selective PCAF inhibitor ameliorates cognitive and behavioral deficits by suppressing NF-κB-mediated neuroinflammation induced by Aβ in a model of Alzheimer's disease
  publication-title: Bioorg. Chem.
– volume: 34
  start-page: 983
  year: 2004
  ident: 10.1016/j.bioorg.2020.103578_b0260
  article-title: In vitro metabolism of gefitinib in human liver microsomes
  publication-title: Xenobiotica
  doi: 10.1080/02772240400015222
– volume: 9
  start-page: 976
  issue: 4
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b1040
  article-title: Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-09-0954
– volume: 53
  start-page: 2025
  year: 1997
  ident: 10.1016/j.bioorg.2020.103578_b0115
  article-title: Polygonapholine, an alkaloid with a novel skeleton, isolated from polygonatum alte-lobatum
  publication-title: Tetrahedron
  doi: 10.1016/S0040-4020(96)01165-9
– start-page: 72
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0960
  publication-title: Cancer Res.
– volume: 35
  start-page: 1135
  year: 2007
  ident: 10.1016/j.bioorg.2020.103578_b0305
  article-title: Timolol metabolism in human liver microsomes is mediated principally by CYP2D6
  publication-title: Drug Metab. Dispos.
  doi: 10.1124/dmd.106.012906
– volume: 12
  start-page: 151
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b1100
  article-title: VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-12-0466
– volume: 22
  start-page: 6746
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0380
  article-title: Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihydro-5H-thiopyrano[4,3-d] pyrimidine derivatives as mTOR inhibitors
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2014.11.003
– volume: 81
  start-page: 8696
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0080
  article-title: Catalytic asymmetric synthesis of morpholines using mechanistic insights to realize the enantioselective synthesis of piperazines
  publication-title: J. Org. Chem.
  doi: 10.1021/acs.joc.6b01884
– volume: 27
  start-page: 1334
  year: 1999
  ident: 10.1016/j.bioorg.2020.103578_b0285
  article-title: Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes
  publication-title: Drug Metab. Dispos.
  doi: 10.1016/S0090-9556(24)14936-7
– volume: 45
  start-page: 5406
  year: 2002
  ident: 10.1016/j.bioorg.2020.103578_b0580
  article-title: Nitric oxide-releasing morpholine derivatives as hypolipidemic and antioxidant agents
  publication-title: J. Med. Chem.
  doi: 10.1021/jm011062i
– volume: 6
  start-page: 60
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b0715
  article-title: Evaluation of benzophenone-N-ethyl morpholine ethers as antibacterial and antifungal activities
  publication-title: J. Chem. Int. J. Biomed. Sci.
  doi: 10.59566/IJBS.2010.6060
– volume: 48
  start-page: 7
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0005
  article-title: Heterocycles in drugs and drug discovery
  publication-title: Chem. Heterocycl. Compd.
  doi: 10.1007/s10593-012-0960-z
– volume: 20
  start-page: 109
  issue: 1
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0990
  article-title: A phase Ib study of Pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
  publication-title: Breast Cancer Res.
  doi: 10.1186/s13058-018-1015-x
– volume: 5
  start-page: 24997
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0705
  article-title: Dihydropyrazoles containing morpholine: design, synthesis and bioassay testing as potent antimicrobial agents
  publication-title: RSC Adv.
  doi: 10.1039/C4RA15201H
– volume: 2
  start-page: 774
  year: 2011
  ident: 10.1016/j.bioorg.2020.103578_b1065
  article-title: Identification of NVP-BKM120 as a Potent, selective, orally bioavailable class I PI3 kinase inhibitor for treating cancer
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/ml200156t
– volume: 96
  start-page: 382
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0440
  article-title: Synthesis and antitumor activities evaluation of m-(4-morpholinoquinazolin-2-yl)benzamides in vitro and in vivo
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2015.04.037
– volume: 4
  start-page: 778
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0710
  article-title: Synthesis, antimicrobial and antioxidant activities of novel series of cinnamamide derivatives having morpholine moiety
  publication-title: Med. Chem.
– volume: 14
  start-page: 1234
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0105
  article-title: Intramolecular Pd(II) catalyzed aerobic oxidative amination of alkenes: synthesis of six-membered N-heterocycles
  publication-title: Org. Lett.
  doi: 10.1021/ol300030w
– volume: 41
  start-page: 5
  year: 1995
  ident: 10.1016/j.bioorg.2020.103578_b0120
  publication-title: Heterocycles
  doi: 10.3987/COM-94-6917
– volume: 167
  start-page: 324
  year: 2019
  ident: 10.1016/j.bioorg.2020.103578_b0250
  article-title: Revealing quinquennial anticancer journey of morpholine: a SAR based review
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2019.02.015
– volume: 22
  start-page: 5114
  issue: 15
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b1165
  article-title: Conformationally-restricted cyclic sulfones as potent and selective mTOR kinase inhibitors
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2012.05.104
– volume: 24
  start-page: 86
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0745
  article-title: New drugs and perspectives for new anti-tuberculosis regimens
  publication-title: Pulmonology
  doi: 10.1016/j.rppnen.2017.10.009
– volume: 151
  start-page: 401
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0345
  article-title: Therapeutic journey of nitrogen mustard as alkylating anticancer agents: historic to future perspectives
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2018.04.001
– volume: 42
  start-page: 482
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0415
  article-title: Synthesis and biological evaluation of novel chalcones bearing morpholine moiety as antiproliferative agents
  publication-title: Turk. J. Chem.
– volume: 64
  start-page: 9152
  year: 2004
  ident: 10.1016/j.bioorg.2020.103578_b0875
  article-title: Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-04-2727
– volume: 55
  start-page: 493
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b0515
  article-title: Two 6-(propan-2-yl)-4-methyl-morpholine-2,5-diones as new non-purine xanthine oxidase inhibitors and anti-inflammatory agents
  publication-title: Food Chem. Toxicol.
  doi: 10.1016/j.fct.2013.01.052
– ident: 10.1016/j.bioorg.2020.103578_b0755
– volume: 29
  start-page: 945
  year: 1999
  ident: 10.1016/j.bioorg.2020.103578_b0270
  article-title: Human moricizine metabolism. II. Quantification and pharmacokinetics of plasma and urinary metabolites
  publication-title: Xenobiotica
  doi: 10.1080/004982599238182
– volume: 11
  start-page: 507
  year: 2005
  ident: 10.1016/j.bioorg.2020.103578_b0940
  article-title: PI 3-kinase p110beta: a new target for antithrombotic therapy
  publication-title: Nat. Med.
  doi: 10.1038/nm1232
– volume: 84
  start-page: 255
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0215
  article-title: Synthesis and biological activity of new [1,3]thiazolo[4,5-d]pyridazin-4(5H)-ones
  publication-title: Sci. Pharm.
  doi: 10.3797/scipharm.1505-16
– volume: 9
  start-page: 1162
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0610
  article-title: Antioxidant and oxidative stress: a mutual interplay in age-related diseases
  publication-title: Front Pharmacol.
  doi: 10.3389/fphar.2018.01162
– volume: 24
  start-page: 5444
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0330
  article-title: Synthesis of multifunctional spirocyclic azetidines and their application in drug discovery
  publication-title: Chemistry
  doi: 10.1002/chem.201800193
– volume: 32
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0965
  article-title: Phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors
  publication-title: J. Clin. Oncol.
  doi: 10.1200/jco.2014.32.15_suppl.2514
– volume: 2018
  start-page: 9872095
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0805
  article-title: Current visceral leishmaniasis research: a research review to inspire future study
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2018/9872095
– volume: 23
  start-page: 5981
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0955
  article-title: The first-time-in-human study of gsk2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumours
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-17-0725
– volume: 61
  start-page: 10084
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b1195
  article-title: Discovery and preclinical characterization of 5–[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a highly potent and selective mTORC1/2 inhibitor for cancer and neurological disorders
  publication-title: J. Med. Chem.
  doi: 10.1021/acs.jmedchem.8b01262
– volume: 140
  start-page: 92
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0500
  article-title: TNF-α and IL-6 inhibitors: conjugates of N-substituted indole and aminophenylmorpholin-3-one as anti-inflammatory agents
  publication-title: Eur. J. Med. Chem.
  doi: 10.1016/j.ejmech.2017.09.003
– volume: 22
  start-page: 2416
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0480
  article-title: 1,2-benzisothiazol-3-one derivatives as a novel class of small-molecule caspase-3 inhibitors
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2014.03.002
– volume: 9
  start-page: 55
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0680
  article-title: Synthesis, characterization and antimicrobial evaluation of novel 2-pyrazoline derivatives containing morpholine moiety
  publication-title: Der. Pharmacia. Lett.
– volume: 67
  start-page: 5840
  year: 2007
  ident: 10.1016/j.bioorg.2020.103578_b0985
  article-title: Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-4615
– volume: 19
  start-page: 5679
  year: 2011
  ident: 10.1016/j.bioorg.2020.103578_b0040
  article-title: Synthesis and glycosidase inhibitory profiles of functionalized morpholines and oxazepanes
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2011.07.019
– volume: 8
  start-page: 2894
  year: 2009
  ident: 10.1016/j.bioorg.2020.103578_b0885
  article-title: Improved ATM kinase inhibitor ku-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-09-0519
– volume: 9
  start-page: 50
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0770
  article-title: Development of new pyrazole hybrids as antitubercular agents: synthesis, biological evaluation and molecular docking study
  publication-title: Int. J. Pharm. Pharm. Sci.
  doi: 10.22159/ijpps.2017v9i11.20469
– volume: 3
  start-page: 462
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0800
  article-title: Design and synthesis of novel N-substituted morpholino benzamide derivatives as antimicrobial agents
  publication-title: Der. Pharmacia. Sinica
– volume: 36
  start-page: 2518
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b1190
  article-title: A phase Ia/Ib trial of the DNA-PK inhibitor M3814 in combination with radiotherapy (RT) in patients (pts) with advanced solid tumors: dose-escalation results
  publication-title: J. Clin. Onco.
  doi: 10.1200/JCO.2018.36.15_suppl.2518
– year: 2019
  ident: 10.1016/j.bioorg.2020.103578_b0255
  article-title: Morpholine as a privileged structure: a review on the medicinal chemistry and pharmacological activity of morpholine containing bioactive molecules
  publication-title: Med. Res. Rev.
– volume: 55
  start-page: 5483
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0585
  article-title: Cholesterol biosynthesis: a mechanistic overview
  publication-title: Biochemistry
  doi: 10.1021/acs.biochem.6b00342
– volume: 26
  start-page: 1195
  issue: 6
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b1115
  article-title: The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
  publication-title: Leukemia
  doi: 10.1038/leu.2011.339
– volume: 105
  start-page: 90
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b1070
  article-title: Inhibition of mTOR's catalytic site by pki-587 is a promising therapeutic option for gastro entero pancreatic neuroendocrine tumor disease
  publication-title: Neuroendocrinology
  doi: 10.1159/000448843
– year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b1160
  article-title: mTOR kinase: a possible pharmacological target in the management of chronic pain
  publication-title: Biomed. Res. Int.
  doi: 10.1155/2015/394257
– volume: 6
  start-page: 225
  year: 1996
  ident: 10.1016/j.bioorg.2020.103578_b0295
  article-title: The role of cytochrome P450 2D6 in the metabolism of moclobemide
  publication-title: Eur. Neuropsychopharmacol.
  doi: 10.1016/0924-977X(96)00023-5
– volume: 5
  start-page: 253
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0435
  article-title: Synthesis and evaluation of 5-chloro-2-methoxy-N-(4-sulphamoylphenyl)benzamide derivatives as anti-cancer agents
  publication-title: Med. Chem.
  doi: 10.4172/2161-0444.1000272
– ident: 10.1016/j.bioorg.2020.103578_b0535
– volume: 22
  start-page: 6746
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0460
  article-title: Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7,8-dihyd ro-5H-thiopyrano[4,3-d] pyrimidine derivatives as mTOR inhibitors
  publication-title: Bioorg. Med. Chem.
  doi: 10.1016/j.bmc.2014.11.003
– volume: 132
  start-page: 543
  issue: 5
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b1170
  article-title: Drug discovery targeting the mTOR pathway
  publication-title: Clin. Sci. (Lond)
  doi: 10.1042/CS20171158
– volume: 4
  start-page: 103
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b1175
  article-title: Discovery and biological profiling of potent and selective mTOR inhibitor GDC-0349
  publication-title: ACS Med. Chem. Lett.
  doi: 10.1021/ml3003132
– ident: 10.1016/j.bioorg.2020.103578_b0660
  doi: 10.1021/jm501100b
– ident: 10.1016/j.bioorg.2020.103578_b0220
– volume: 16
  start-page: 555
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0205
  article-title: The mechanistic targets of antifungal agents: an overview
  publication-title: Mini Rev. Med. Chem.
  doi: 10.2174/1389557516666160118112103
– ident: 10.1016/j.bioorg.2020.103578_b0185
  doi: 10.1007/s11255-017-1507-0
– volume: 8
  start-page: 627
  issue: 8
  year: 2009
  ident: 10.1016/j.bioorg.2020.103578_b0395
  article-title: Targeting the phosphoinositide 3-kinase pathway in cancer
  publication-title: Nat Rev Drug Discov.
  doi: 10.1038/nrd2926
– volume: 20
  start-page: 2408
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b1005
  article-title: Identification of GNE-477, a potent and efficacious dual pi3k/mtor inhibitor
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2010.03.046
– volume: 58
  start-page: 258
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0190
  article-title: Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factor
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01677-13
– volume: 93
  start-page: 1011
  year: 2005
  ident: 10.1016/j.bioorg.2020.103578_b0855
  article-title: Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6602823
– volume: 20
  start-page: 5908
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b1085
  article-title: The first-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-14-1315
– volume: 35
  start-page: 639
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0895
  article-title: Improved synthesis of a DNA-dependent protein kinase inhibitor IC86621
  publication-title: Arch. Pharm. Res.
  doi: 10.1007/s12272-012-0407-1
– volume: 2014
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b1105
  article-title: Differential role of rapamycin and Torin/KU63794 in inflammatory response of 264.7 RAW macrophages stimulated by CA-MRSA
  publication-title: Int. J. Inflam.
– volume: 26
  start-page: 2649
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0775
  article-title: Click-based synthesis and antitubercular evaluation of novel dibenzo[b, d]thiophene-1,2,3-triazoles with piperidine, piperazine, morpholine and thiomorpholine appendages
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2016.04.015
– volume: 56
  start-page: 2125
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b1185
  article-title: Discovery of 4-{4-[(3R)-3-methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1h-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity
  publication-title: J. Med. Chem.
  doi: 10.1021/jm301859s
– volume: 80
  start-page: 4349
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0095
  article-title: Synthesis of five-, six-, and seven-membered 1,3-and 1,4-heterocyclic compounds via intramolecular hydrothioalkoxylation of alkenols/thioalkenols
  publication-title: J. Org. Chem.
  doi: 10.1021/acs.joc.5b00049
– volume: 5
  start-page: 544
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0245
  article-title: Development of novel benzo morpholine class of diacylglycerol acyltransferase I inhibitors
  publication-title: Med. Chem. Lett.
  doi: 10.1021/ml400527n
– volume: 129
  start-page: 57
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b1060
  article-title: Treatment with the PI3K inhibitor buparlisib (NVP-BKM120) suppresses the growth of established patient-derived GBM xenografts and prolongs survival in nude rats
  publication-title: J. Neurooncol.
  doi: 10.1007/s11060-016-2158-1
– ident: 10.1016/j.bioorg.2020.103578_b0815
– volume: 17
  start-page: 5044
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0085
  article-title: Synthesis of 6- and 7-membered N-heterocycles using α-phenylvinylsulfonium salts
  publication-title: Org. Lett.
  doi: 10.1021/acs.orglett.5b02516
– volume: 2004
  start-page: 641
  year: 2004
  ident: 10.1016/j.bioorg.2020.103578_b0225
  article-title: Biological relevance and synthesis of C-substituted morpholine derivatives
  publication-title: Synthesis
  doi: 10.1055/s-2004-816003
– volume: 27
  start-page: 66
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0425
  article-title: Synthesis of new morpholine-connected pyrazolidine derivatives and their antimicrobial, antioxidant, and cytotoxic activities
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2016.11.032
– volume: 10
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0765
  article-title: Advances in drug discovery of new antitubercular multidrug-resistant compounds
  publication-title: Pharmaceuticals (Basel)
  doi: 10.3390/ph10020051
– volume: 3
  start-page: 114
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0640
  article-title: Design and synthesis of some enaminonitrile derivatives of antipyrine as potential novel anti-inflammatory and analgesic agents
  publication-title: J. Biosci. Med.
– ident: 10.1016/j.bioorg.2020.103578_b0370
– volume: 20
  start-page: 653
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b1035
  article-title: Novel imidazolopyrimidines as dual PI3-kinase/mTOR inhibitors
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2009.11.057
– volume: 50
  start-page: 606
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0830
  article-title: PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells
  publication-title: Int. J. Oncol.
  doi: 10.3892/ijo.2016.3804
– volume: 8
  start-page: 252
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0785
  article-title: Synthesis and antitubercular activity of piperidine and morpholine 1, 8 naphthyridine analogues
  publication-title: Int. J. Pharm. Pharm. Sci.
  doi: 10.22159/ijpps.2016v8i12.13503
– volume: 54
  start-page: 185
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0910
  article-title: The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy
  publication-title: Pathol. Biol. (Paris)
  doi: 10.1016/j.patbio.2006.01.012
– volume: 19
  start-page: 4696
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0075
  article-title: Continuous flow synthesis of morpholines and oxazepanes with silicon amine protocol (slap) reagents and Lewis acid facilitated photoredox catalysis
  publication-title: Org. Lett.
  doi: 10.1021/acs.orglett.7b02395
– volume: 53
  start-page: 3227
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b0315
  article-title: Oxetanes in drug discovery: structural and synthetic insights
  publication-title: J. Med. Chem.
  doi: 10.1021/jm9018788
– volume: 6
  start-page: 60
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b0530
  article-title: Synthesis of benzophenone-n-ethyl morpholine ethers as anti-inflammatory agents
  publication-title: Int. J. Biomed. Sci.
  doi: 10.59566/IJBS.2010.6060
– volume: 2
  start-page: 1257
  year: 2003
  ident: 10.1016/j.bioorg.2020.103578_b0915
  article-title: DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer
  publication-title: Mol. Cancer Ther.
– volume: 51
  start-page: 1800098
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0750
  article-title: The world health organization standards for tuberculosis care and management
  publication-title: Eur. Respir. J.
  doi: 10.1183/13993003.00098-2018
– volume: 68
  start-page: 206
  year: 2008
  ident: 10.1016/j.bioorg.2020.103578_b0845
  article-title: Vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-07-0669
– start-page: 2939
  year: 2011
  ident: 10.1016/j.bioorg.2020.103578_b0045
  article-title: Synthesis of a chiral key intermediate of neurokinin antagonist SSR 240600 by asymmetric allylic alkylation
  publication-title: Synlett
– volume: 59
  start-page: 1868
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b0780
  article-title: Mycobacterium tuberculosis Gyrase inhibitors as a new class of antitubercular drugs
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.03913-14
– volume: 47
  start-page: 4512
  year: 2008
  ident: 10.1016/j.bioorg.2020.103578_b0320
  article-title: Spirocyclic oxetanes: synthesis and properties
  publication-title: Angew. Chem. Int. Ed.
  doi: 10.1002/anie.200800450
– volume: 149
  start-page: 387
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b1045
  article-title: Determination of ZSTK474, a novel Pan PI3K inhibitor in mouse plasma by LC-MS/MS and its application to Pharmacokinetics
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2017.11.031
– ident: 10.1016/j.bioorg.2020.103578_b0210
  doi: 10.4103/0250-474X.57292
– volume: 103
  start-page: 4659
  year: 2004
  ident: 10.1016/j.bioorg.2020.103578_b0860
  article-title: A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia
  publication-title: Blood
  doi: 10.1182/blood-2003-07-2527
– volume: 40
  start-page: 641
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0650
  article-title: Synthesis of novel thiazolylpyrazoline derivatives and evaluation of their antimicrobial activities and cytotoxicities
  publication-title: Turk. J. Chem.
  doi: 10.3906/kim-1512-12
– volume: 12
  start-page: 25
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0810
  article-title: Leishmaniasis in humans: drug or vaccine therapy?
  publication-title: Drug Des. Devel. Ther.
  doi: 10.2147/DDDT.S146521
– volume: 96
  start-page: 719
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0820
  article-title: 1,2,4-triazole derivatives with morpholine; DFT study and antileishmanial activity
  publication-title: Canadian J. Phys.
  doi: 10.1139/cjp-2017-0710
– volume: 57
  start-page: 903
  year: 2014
  ident: 10.1016/j.bioorg.2020.103578_b0975
  article-title: Discovery and optimization of pyrimidone indoline amide pi3kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers
  publication-title: J. Med. Chem.
  doi: 10.1021/jm401642q
– volume: 54
  start-page: 7105
  year: 2011
  ident: 10.1016/j.bioorg.2020.103578_b0410
  article-title: Synthesis and biological evaluation of novel analogues of the pan class I phosphatidylinositol-3-kinase (PI3K) inhibitor 2-(difluoromethyl)-1-[4,6-di(4-morpholinyl)-1,3, 5-triazin-2-yl]-1H-benzimidazole (ZSTK474)
  publication-title: J. Med. Chem.
  doi: 10.1021/jm200688y
– volume: 31
  start-page: 5501
  year: 2003
  ident: 10.1016/j.bioorg.2020.103578_b0900
  article-title: Vanillins, novel family of DNA-PK inhibitors
  publication-title: Nucleic Acids Res.
  doi: 10.1093/nar/gkg753
– volume: 80
  start-page: 727
  year: 2018
  ident: 10.1016/j.bioorg.2020.103578_b0625
  article-title: Antimicrobial, antioxidant and DNA interaction studies of water-soluble complexes of Schiff base bearing morpholine moiety
  publication-title: Indian J. Pharm. Sci.
  doi: 10.4172/pharmaceutical-sciences.1000413
– volume: 22
  start-page: 1211
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0420
  article-title: Synthesis, antitumor evaluation and molecular docking of new morpholine based heterocycles
  publication-title: Molecules
  doi: 10.3390/molecules22071211
– volume: 56
  start-page: 3330
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b0590
  article-title: New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz) oxazine derivatives with antioxidant, anti hyperlipidemic, and antidiabetic action
  publication-title: J. Med. Chem.
  doi: 10.1021/jm400101e
– ident: 10.1016/j.bioorg.2020.103578_b1095
  doi: 10.1371/journal.pone.0132655
– volume: 284
  start-page: 33763
  year: 2009
  ident: 10.1016/j.bioorg.2020.103578_b0950
  article-title: Role of phosphoinositide 3-kinase beta in glycoprotein VI-mediated Akt activation in platelets
  publication-title: J. Biol. Chem.
  doi: 10.1074/jbc.M109.048553
– volume: 22
  start-page: 3629
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b0720
  article-title: Antimicrobial and antiurease activities of newly synthesized morpholine derivatives containingan azole nucleus
  publication-title: Med. Chem. Res.
  doi: 10.1007/s00044-012-0318-1
– volume: 66
  start-page: 5354
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0850
  article-title: Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-05-4275
– volume: 70
  start-page: 288
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b1125
  article-title: AZD8055 is a potent, selective, and orally bioavailable atp-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-09-1751
– volume: 23
  start-page: 1212
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b1120
  article-title: Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2013.01.019
– volume: 10
  start-page: 2127
  year: 2012
  ident: 10.1016/j.bioorg.2020.103578_b0945
  article-title: Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD 6482 a novel PI3Kβ inhibitor
  publication-title: J. Thromb. Haemost.
  doi: 10.1111/j.1538-7836.2012.04898.x
– volume: 14
  start-page: 2508
  year: 2015
  ident: 10.1016/j.bioorg.2020.103578_b1130
  article-title: AZD2014, an inhibitor of mtorc1 and mtorc2, is highly effective in breast cancer when administered using intermittent or continuous schedules
  publication-title: Mol. Cancer Ther.
  doi: 10.1158/1535-7163.MCT-15-0365
– ident: 10.1016/j.bioorg.2020.103578_b0760
  doi: 10.1021/acs.jmedchem.8b00172
– volume: 31
  start-page: 66
  issue: 1
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b1020
  article-title: Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases
  publication-title: Invest. New Drugs
  doi: 10.1007/s10637-012-9835-5
– ident: 10.1016/j.bioorg.2020.103578_b0655
– volume: 135
  start-page: 479
  year: 2013
  ident: 10.1016/j.bioorg.2020.103578_b0890
  article-title: Predictability, efficacy and safety of radiosensitization of glioblastoma-initiating cells by the ATM inhibitor KU-60019
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.28680
– volume: 17
  start-page: 3193
  year: 2011
  ident: 10.1016/j.bioorg.2020.103578_b1075
  article-title: Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-10-1694
– volume: 53
  start-page: 4731
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b0055
  article-title: Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation
  publication-title: J. Med. Chem.
  doi: 10.1021/jm1003232
– volume: 54
  start-page: 7579
  year: 2011
  ident: 10.1016/j.bioorg.2020.103578_b1015
  article-title: Discovery of a potent, selective, and orally available class i phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mtor) kinase inhibitor (GDC-0980) for the treatment of cancer
  publication-title: J. Med. Chem.
  doi: 10.1021/jm2009327
– volume: 102
  start-page: 606
  year: 1986
  ident: 10.1016/j.bioorg.2020.103578_b0145
  article-title: Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978–1985
  publication-title: Amer. J. Ophthalmol.
  doi: 10.1016/0002-9394(86)90532-5
– volume: 128
  start-page: 485
  year: 2016
  ident: 10.1016/j.bioorg.2020.103578_b0275
  publication-title: J. Pharm. Biomed. Anal.
  doi: 10.1016/j.jpba.2016.06.011
– volume: 256
  start-page: 34
  year: 2000
  ident: 10.1016/j.bioorg.2020.103578_b0400
  article-title: Serine/threonine protein kinases and apoptosis
  publication-title: Exp. Cell Res.
  doi: 10.1006/excr.2000.4836
– volume: 6
  start-page: 31
  year: 2017
  ident: 10.1016/j.bioorg.2020.103578_b0155
  article-title: Monoamine oxidase inhibitors—revisiting a therapeutic principle
  publication-title: Open J. Depress.
  doi: 10.4236/ojd.2017.62004
– volume: 65
  start-page: 4987
  year: 2005
  ident: 10.1016/j.bioorg.2020.103578_b0905
  article-title: DNA-dependent protein kinase is a molecular target for the development of non-cytotoxic radiation-sensitizing drugs
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-04-4250
– volume: 20
  start-page: 2644
  year: 2010
  ident: 10.1016/j.bioorg.2020.103578_b0390
  article-title: Discovery of 2-ureido phenyl triazines bearing bridged morpholines as potent and selective ATP-competitive mTOR inhibitors
  publication-title: Bioorg. Med. Chem. Lett.
  doi: 10.1016/j.bmcl.2010.02.045
– ident: 10.1016/j.bioorg.2020.103578_b0160
SSID ssj0011476
Score 2.5840282
SecondaryResourceType review_article
Snippet [Display omitted] •Morpholine is a versatile nucleus as it involved in wide range of pharmacological activities.•The present review covers synthetic medicinal...
Morpholine is a versatile moiety, a privileged pharmacophore and an outstanding heterocyclic motif with wide ranges of pharmacological activities due to...
SourceID proquest
pubmed
crossref
elsevier
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 103578
SubjectTerms Chemistry, Pharmaceutical
Drug Design
Humans
Morpholine
Morpholines - chemistry
Morpholines - pharmacology
Pharmacokinetic
Pharmacological profile
Pharmacophore
Structure-Activity Relationship
Structure–activity relationship (SAR)
Title Morpholine as ubiquitous pharmacophore in medicinal chemistry: Deep insight into the structure-activity relationship (SAR)
URI https://dx.doi.org/10.1016/j.bioorg.2020.103578
https://www.ncbi.nlm.nih.gov/pubmed/31978684
https://www.proquest.com/docview/2345507781
Volume 96
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Baden-Württemberg Complete Freedom Collection (Elsevier)
  customDbUrl:
  eissn: 1090-2120
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0011476
  issn: 0045-2068
  databaseCode: GBLVA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier ScienceDirect
  customDbUrl:
  eissn: 1090-2120
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0011476
  issn: 0045-2068
  databaseCode: .~1
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Complete Freedom Collection [SCCMFC]
  customDbUrl:
  eissn: 1090-2120
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0011476
  issn: 0045-2068
  databaseCode: ACRLP
  dateStart: 19950301
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals [SCFCJ]
  customDbUrl:
  eissn: 1090-2120
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0011476
  issn: 0045-2068
  databaseCode: AIKHN
  dateStart: 19950301
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
– providerCode: PRVLSH
  databaseName: Elsevier Journals
  customDbUrl:
  mediaType: online
  eissn: 1090-2120
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0011476
  issn: 0045-2068
  databaseCode: AKRWK
  dateStart: 19710901
  isFulltext: true
  providerName: Library Specific Holdings
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaqcoALgj5ggVauhCp6MG02foXbaqFaHq1QoVJvll-BIEjCPg5w4Ld3JolXQqKqxMlKbMuWZzKPeL4ZQp7LqE88OF0sZDZnnJeBWUSjxUIILzPHM43Y4bNzObvk767E1QaZJiwMhlUOsr-X6Z20Ht4cD6d53FYVYny5GJ9IUGnIlwUCzTH7F_D0yz_rMA8w97sCcziY4egEn-tivFzVNPMv4CWOO_S5wGJr_1ZPN5mfnRo6fUDuD_YjnfRbfEg2Yr1Ftic1-M4_ftFD2kV0dr_Kt8jdaarmtk1-nzVwolihJ1K7oCtX_VzBx7xa0HZIXg2980irmg7X7bCKT_Nf0dcxttC5QF8e2mVDwXKkffbZ1TwyxEdgGQo6T9F1X6uWvvg0uTjaIZenbz5PZ2you8A8qLMl4zbz1ueFK52UNiiHRowOaqyFjQH8q-CEjmi6qQJTvokiC7rMrNRegXiQ-S7ZrJs6PibUgrniNbeiDI57G60sdalkFixXTkU3Ink6buOHpORYG-O7SdFn30xPJINEMj2RRoStZ7V9Uo5bxqtESfMXcxnQG7fMPEiEN3DgeJli6wjEMeMc8eBK6WxEHvUcsd4LiDWlpeZP_nvdp-QePvXBbs_IJlAz7oH1s3T7HXvvkzuT6cWHj9i-fT87vwae8gdK
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6V7aFcKtryWKBgJITgELXZ-JXeVluqLe3uAVqpN8t2nBJEk7CPA_x6ZvJYCQlUiVOk2Jatmck84vlmAN7KoI89Bl1RFtsk4jzPIktotJAK4WXseKwJOzyby-k1_3QjbrZg0mNhKK2y0_2tTm-0dffmqKPmUV0UhPHlYnQs0aSRXKbiAWxzgTp5ANvj84vpfHOZEPOmxxzNj2hBj6Br0rxcUVWLWwwURw0AXVC_tb9bqH95oI0lOnsEu50LycbtKfdgK5T7cDAuMXy--8nesSaps_lbvg87k76h2wH8mlVIVGrSE5hdsrUrfqzxe14vWd3Vr8bRRWBFybobd9zF9-tP2GkINQ4uKZzH56pi6DyytgDtehEigkhQJwq26BPsvhY1e_9l_PnDY7g--3g1mUZd64XIo0VbRdzG3vokdbmT0mbKkR-jMzXSwoYMQ6zMCR3Ie1MpVX0TaZzpPLZSe4UaQiZPYFBWZXgGzKLH4jW3Is8c9zZYmetcyTizXDkV3BCSntzGd3XJqT3Gd9MnoH0zLZMMMcm0TBpCtFlVt3U57pmvek6aP-TLoOm4Z-WbnvEGCU73KbYMyBwzSggSrpSOh_C0lYjNWVCzKS01f_7f-76GnenV7NJcns8vXsBDGmlz317CADkbDtEZWrlXnbD_BkXrCGA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Morpholine+as+ubiquitous+pharmacophore+in+medicinal+chemistry%3A+Deep+insight+into+the+structure-activity+relationship+%28SAR%29&rft.jtitle=Bioorganic+chemistry&rft.au=Kumari%2C+Archana&rft.au=Singh%2C+Rajesh+K&rft.date=2020-03-01&rft.issn=1090-2120&rft.eissn=1090-2120&rft.volume=96&rft.spage=103578&rft_id=info:doi/10.1016%2Fj.bioorg.2020.103578&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0045-2068&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0045-2068&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0045-2068&client=summon